[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_e0fc6afa-a88c-4f20-be20-f21b1a823b4d":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:e0fc6afa-a88c-4f20-be20-f21b1a823b4d,\"}":98},{"code":4,"data":5,"meta":18},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":20,"manageAffiliations":29,"indexDatabases":53,"url":18,"thumbnailPath":18,"statistic":92,"gsStatistic":18,"type":18,"analyzePriority":18},"e0fc6afa-a88c-4f20-be20-f21b1a823b4d","2024-04-06T07:59:15.399+00:00","2025-11-21T10:02:43.397+00:00",[],"Psychiatric-Clinics-of-North-America",{"issn":12,"title":14},{"VOID":13},"0193953X",{"EN":15},"Psychiatric Clinics of North America","PUBLISHER","PENDING",null,0,[21],{"id":22,"createTime":23,"updateTime":24,"relativeEntities":25,"label":26,"description":28,"parentId":18,"standard":18,"scholarHubFieldId":18},"0e4edeee-4f2c-4c5b-932c-1b4842536341","2023-05-29T10:24:08.227+00:00","2023-11-21T07:30:08.928+00:00",[],{"EN":27},"Psychiatry and Mental Health",{},[30,42],{"id":31,"createTime":32,"updateTime":33,"relativeEntities":34,"slug":35,"properties":36,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":40,"url":18,"parentIds":41,"statistic":18},"c5cf455f-38f5-4f40-bf6f-38a42a0749ef","2023-05-29T10:24:06.260+00:00","2025-11-21T10:07:18.982+00:00",[],"W-B-Saunders-Ltd",{"title":37},{"EN":38},"W.B. Saunders Ltd","AFFILIATION",14,[],{"id":43,"createTime":44,"updateTime":45,"relativeEntities":46,"slug":47,"properties":48,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":51,"url":18,"parentIds":52,"statistic":18},"73b223dd-43c7-44ac-995c-3775b6b8aa68","2023-05-29T12:07:44.207+00:00","2024-02-19T19:17:51.038+00:00",[],"W-B-SAUNDERS-CO-ELSEVIER-INC",{"title":49},{"EN":50},"W B SAUNDERS CO-ELSEVIER INC",9,[],[54,73],{"id":55,"indexDatabase":56,"url":68,"indexYears":69,"academicFieldIds":70,"indexDatabaseRanking":72},"121908ca-066c-4e5e-9db0-e865db5689da",{"id":57,"createTime":58,"updateTime":59,"relativeEntities":60,"label":61,"description":63,"key":65,"publicationTags":66,"standard":18},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":62,"VI":62},"Scopus - Elsevier",{"EN":62,"VI":64},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[67],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F18687","1978-2025",[71],"c6aa5b1f-2a2b-4eb1-8a8f-f81f3c8c8061","SCOPUS__Q2",{"id":74,"indexDatabase":75,"url":89,"indexYears":18,"academicFieldIds":90,"indexDatabaseRanking":18},"96927940-6601-4837-a9f7-6b9c692b5ad9",{"id":76,"createTime":77,"updateTime":78,"relativeEntities":79,"label":80,"description":82,"key":85,"publicationTags":86,"standard":18},"a8273be3-1221-4f26-949d-71dc71ff1fc3","2023-05-22T09:59:54.622+00:00","2025-11-21T10:07:52.181+00:00",[],{"EN":81,"VI":81},"ISI-SSCI -  Social Sciences Citation Index",{"VI":83,"EN":84},"Cơ sở dữ liệu SSCI","SSCI database","ssci",[87,88],"SSCI","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=0193-953X",[91],"99374084-23d1-4b73-aae8-d96feb1e8677",{"impactFactor":19,"impactFactorByYear":93,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":95,"totalCitation":19,"totalCitationByYear":96,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":97,"hindexLast5Year":19,"hindex":19},{},1,{"1992":94},{},{},{"meta":99,"data":101},{"total":100},"651",[102,171,249,337,433,513,577,657,763,1252],{"id":103,"createTime":104,"updateTime":105,"relativeEntities":106,"slug":107,"properties":108,"entityType":115,"verifyStatus":17,"verifyTime":105,"verifyNote":116,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":117,"fullTextUrl":18,"authors":118,"publicationType":134,"publisherRelationship":135,"citationCount":18,"citationInfo":18,"publishDate":168,"publishYear":169,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":170},"c609b61e-828d-4ecf-9fc2-530b6e6e93e1","2023-12-23T12:00:41.031+00:00","2025-01-21T23:58:24.642+00:00",[],"THE-BIOLOGY-OF-IMPULSIVITY-AND-SUICIDALITY",{"references":109,"title":111,"doi":113},{"VOID":110},"Agren, 1980, Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid. II. Suicide, Psychiatry Res, 3, 225, 10.1016\u002F0165-1781(80)90039-6\nAÅsberg, 1987, Psychobiology of suicide, impulsivity, and related phenomena, 655\nArango, 1997, Postmortem findings in suicide victims: Implications for in vivo imaging studies, Ann N Y Acad Sci, 836, 269, 10.1111\u002Fj.1749-6632.1997.tb52365.x\nBreese, 1990, Pharmacological evaluation of SCH-12679: Evidence for an in vivo antagonism of D1-dopamine receptors, J Pharmacol Exp Ther, 252, 558\nBrent, 1988, Risk factors for adolescent suicide: A comparison of adolescent suicide victims with suicidal inpatients, Arch Gen Psychiatry, 45, 581, 10.1001\u002Farchpsyc.1988.01800300079011\nBriley, 1985, Imipramine binding: Its relationship with serotonin uptake and depression, 50\nBrown, 1982, Aggression, suicide and serotonin: Relationships to CSF amine metabolites, Am J Psychiatry, 139, 741, 10.1176\u002Fajp.139.6.741\nBrown, 1986, Cerebrospinal fluid correlates of suicide attempts and aggression, Ann N Y Acad Sci, 487, 175, 10.1111\u002Fj.1749-6632.1986.tb27897.x\nBrown, 1982, Human aggression and suicide: Their relationship to neuropsychiatric diagnoses and serotonin metabolism, Adv Biochem Psychopharmacol, 34, 287\nBrunner, 1993, Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A, Science, 262, 578, 10.1126\u002Fscience.8211186\nBuresi C, Courtet PH, Leboyer M, et al: Association between suicide attempt and the trytophane hydroxylase (TPH) gene ‘abstract 270’. Presented at the Annual Meeting of the American Society of Human Genetics, 1997\nCases, 1995, Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA, Science, 268, 1763, 10.1126\u002Fscience.7792602\nChamberlain, 1987, The effect of raising or lowering tryptophan levels on aggression in Vervet monkeys, Pharmacol Biochem Behav, 28, 503, 10.1016\u002F0091-3057(87)90513-2\nCheetham, 1989, Serotonin concentrations and turnover in brains of depressed suicides, Brain Res, 502, 332, 10.1016\u002F0006-8993(89)90629-X\nCheetham, 1990, Brain 5-HT1 binding sites in depressed suicides, Psychopharmacology (Berl), 102, 544, 10.1007\u002FBF02247138\nCoccaro, 1989, Central serotonin and impulsive aggression, Br J Psychiatry, 155, 52, 10.1192\u002FS0007125000291769\nCochran, 1976, Regional serotonin levels in brain: A comparison of depressive suicides and alcoholic suicides with controls, Biol Psychiatry, 11, 283\nCrow, 1984, Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides, Neuropharmacology, 23, 1561, 10.1016\u002F0028-3908(84)90100-X\nDepue, 1986, Conceptualizing a serotonin trait: A behavioral dimension of constraint, Ann N Y Acad Sci, 487, 47, 10.1111\u002Fj.1749-6632.1986.tb27885.x\nDoudet, 1995, Cerebral glucose metabolism, CSF 5-HIAA levels, and aggressive behavior in Rhesus monkeys, Am J Psychiatry, 152, 1782, 10.1176\u002Fajp.152.12.1782\nEgeland, 1985, Suicide and family loading for affective disorders, JAMA, 254, 915, 10.1001\u002Fjama.1985.03360070053022\nEichelman, 1987, Neurochemical and psychopharmacologic aspects of aggressive behavior, 697\nFeldman, 1991, Differential recovery of adrenocortical responses to neural stimuli following administration of 5,7-dihydroxytryptamine into the hypothalamus, Exp Brain Res, 85, 144, 10.1007\u002FBF00229995\nGardner, 1990, CSF metabolites in borderline personality disorder compared with normal controls, Biol Psychiatry, 28, 247, 10.1016\u002F0006-3223(90)90580-U\nGoodwin, 1986, Suicide, aggression, and depression: A theoretical framework for future research, Ann N Y Acad Sci, 487, 351, 10.1111\u002Fj.1749-6632.1986.tb27913.x\nGoyer, 1994, Positron-emission tomography and personality disorders, Neuropsychopharmacology, 10, 21, 10.1038\u002Fnpp.1994.3\nHen, 1993, 5-HT1B receptor “knock out”: Pharmacological and behavioral consequences [abstract], Society for Neuroscience Abstracts, 19, 632\nHrdina, 1993, 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant- free suicide victims\u002Fdepressives: Increase in 5-HT2 sites in cortex and amygdala, Brain Res, 614, 37, 10.1016\u002F0006-8993(93)91015-K\nKraemer, 1990, The behavioral neurobiology of self-injurious behavior in Rhesus monkeys, Prog Neuropsychopharmacol Biol Psychiat, 14, 141, 10.1016\u002F0278-5846(90)90092-U\nLachman, 1998, Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorders, Am J Psychiatry, 155, 835\nLawrence, 1990, Symmetrical hemispheric distribution of 3H-paroxetine binding sites in postmortem human brain from controls and suicides, Biol Psychiatry, 28, 544, 10.1016\u002F0006-3223(90)90492-K\nLinnoila, 1983, Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from non-impulsive violent behavior, Life Sci, 33, 2609, 10.1016\u002F0024-3205(83)90344-2\nLloyd, 1981, Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome, N Engl J Med, 305, 1106, 10.1056\u002FNEJM198111053051902\nMaes, 1995, The Serotonin Hypothesis of Major Depression, 933\nMalone, 1996, Prolactin response to fenfluramine and suicide attempt lethality in major depression, Br J Psychiatry, 168, 324, 10.1192\u002Fbjp.168.3.324\nMann, 1998, The neurobiology of suicide, Nat Med, 4, 25, 10.1038\u002Fnm0198-025\nMann, 1996, Lower 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high-affinity, non-transporter sites, J Neural Transm, 103, 1337, 10.1007\u002FBF01271194\nMann, 1997, Cerebrospinal fluid amines and higher lethality suicide attempts in depressed inpatients, Biol Psychiatry, 41, 162, 10.1016\u002FS0006-3223(96)00217-X\nMann, 1997, Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients, Am J Psychiatry, 154, 1451, 10.1176\u002Fajp.154.10.1451\nMann, 1992, Platelet and whole blood serotonin content in depressed inpatients: Correlations with acute and life-time psychopathology, Biol Psychiatry, 32, 243, 10.1016\u002F0006-3223(92)90106-A\nMann, 1995, Blunted serotonergic responsivity in depressed patients, Neuropsychopharmacology, 13, 53, 10.1016\u002F0893-133X(95)00016-7\nMann JJ, Stanley B, Malone KM: Self-mutilation and suicidal behavior: Biological and psychopathological differences [abstract]. Presented at the Suicide: Biophysical Approaches—International Conference. Athens, Greece, May 1996\nMann, 1996, Postmortem studies of suicide victims, 197\nManuck, 1999, Aggression and anger-related traits associated with a polymorphism of the tryptophan hydroxylase gene, Biol Psychiatry, 45, 603, 10.1016\u002FS0006-3223(98)00375-8\nMatsumoto, 1995, Noradrenergic denervation attenuates desipramine enhancement of aggressive behavior in isolated mice, Pharmacol Biochem Behav, 50, 481, 10.1016\u002F0091-3057(94)00300-8\nMcBride, 1994, The relationship of platelet 5-HT2 receptor indices to major depressive disorder, personality traits, and suicidal behavior, Biol Psychiatry, 35, 295, 10.1016\u002F0006-3223(94)90033-7\nMcKeith, 1987, 5-HT receptor binding in post-mortem brain from patients with affective disorder, J Affect Disord, 13, 67, 10.1016\u002F0165-0327(87)90075-9\nNielsen, 1994, Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism, Arch Gen Psychiatry, 51, 34, 10.1001\u002Farchpsyc.1994.03950010034005\nOquendo, 1999, Serotonergic dysfunction in mood disorders, 121\nOssowska, 1996, Acute effect of dopamine agonists and some antidepressants in stress-induced deficit of fighting behavior, Pol J Pharmacol, 48, 403\nOwen, 1986, Serotonergic mechanisms in brains of suicide victims, Brain Res, 362, 185, 10.1016\u002F0006-8993(86)91415-0\nPickar, 1986, Suicide and aggression in schizophrenia: Neurobiologic correlates, Ann N Y Acad Sci, 487, 189, 10.1111\u002Fj.1749-6632.1986.tb27898.x\nRaine, 1997, Brain abnormalities in murderers indicated by positron emission tomography, Biol Psychiatry, 42, 495, 10.1016\u002FS0006-3223(96)00362-9\nRoy, 1983, Family history of suicide, Arch Gen Psychiatry, 40, 971, 10.1001\u002Farchpsyc.1983.01790080053007\nRoy, 1993, Genetic and biologic risk factors for suicide in depressive disorders, Psychiatr Q, 64, 345, 10.1007\u002FBF01064927\nRoy, 1985, CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide, Psychol Med, 15, 335, 10.1017\u002FS0033291700023618\nRoy, 1989, Suicidal behavior in depression: Relationship to noradrenergic function, Biol Psychiatry, 25, 341, 10.1016\u002F0006-3223(89)90181-9\nRuss, 1992, Self-injurious behavior in patients with borderline personality disorder: Biological perspectives, J Personal Disord, 6, 64, 10.1521\u002Fpedi.1992.6.1.64\nSchiavi, 1984, Sex chromosome anomalies, hormones, and aggressivity, Arch Gen Psychiatry, 41, 93, 10.1001\u002Farchpsyc.1984.01790120097012\nSchulsinger, 1979, A family study of suicide, 277\nSiever, 1993, The serotonin system and aggressive personality disorder, Int Clin Psychopharmacol, 8, 33, 10.1097\u002F00004850-199311002-00005\nSiever, 1999, d,1-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography, Neuropsychopharmacology, 20, 413, 10.1016\u002FS0893-133X(98)00111-0\nSimeon, 1992, Self-mutilation in personality disorders: Psychological and biological correlates, Am J Psychiatry, 149, 221, 10.1176\u002Fajp.149.2.221\nSoloff, 1994, Risk factors for suicidal behavior in borderline personality disorder, Am J Psychiatry, 151, 1316, 10.1176\u002Fajp.151.9.1316\nSzczypka, 1998, Dopamine-stimulated sexual behavior is testosterone dependent in mice, Behav Neurosci, 112, 1229, 10.1037\u002F0735-7044.112.5.1229\nTadano, 1997, Involvement of dopaminergic neurons in mouse-killing aggression in rats, Methods Find Exp Clin Pharmacol, 19, 527\nUnderwood MD, Johnson VL, Wang Y, et al: Increased dorsal raphe nucleus serotonergic neuron process density but no difference in serotonergic neuron number associated with duration of alcoholism [abstract]. Presented at the 37th Annual Meeting of American College of Neuropsychopharmacology. San Juan, 1998\nVirkkunen, 1989, Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters: A follow-up study, Arch Gen Psychiatry, 46, 600, 10.1001\u002Farchpsyc.1989.01810070026003\nWinchel, 1991, Self-injurious behavior: A review of the behavior and biology of self-mutilation, Am J Psychiatry, 148, 306, 10.1176\u002Fajp.148.3.306",{"EN":112},"THE BIOLOGY OF IMPULSIVITY AND SUICIDALITY",{"VOID":114},"10.1016\u002Fs0193-953x(05)70140-4","PUBLICATION","Author affiliation is blank","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0193953X05701404",[119,127],{"id":120,"sortIndex":19,"researcher":18,"roles":121,"affiliations":123,"properties":124},"9600188b-0f79-46f5-b05a-3899a41365fa",[122],"AUTHOR",[],{"title":125},{"VI":126},"Maria A. Oquendo",{"id":128,"sortIndex":94,"researcher":18,"roles":129,"affiliations":130,"properties":131},"19d8aaf0-f4a4-4867-9848-0eedd7b66cda",[122],[],{"title":132},{"VI":133},"J. John Mann","ARTICLE",{"url":117,"publisher":136,"properties":163},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":137,"slug":10,"properties":138,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":141,"manageAffiliations":142,"indexDatabases":143,"url":18,"thumbnailPath":18,"statistic":158,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":139,"title":140},{"VOID":13},{"EN":15},[],[],[144,151],{"id":55,"indexDatabase":145,"url":68,"indexYears":69,"academicFieldIds":150,"indexDatabaseRanking":72},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":146,"label":147,"description":148,"key":65,"publicationTags":149,"standard":18},[],{"EN":62,"VI":62},{"EN":62,"VI":64},[67],[71],{"id":74,"indexDatabase":152,"url":89,"indexYears":18,"academicFieldIds":157,"indexDatabaseRanking":18},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":153,"label":154,"description":155,"key":85,"publicationTags":156,"standard":18},[],{"EN":81,"VI":81},{"VI":83,"EN":84},[87,88],[91],{"impactFactor":19,"impactFactorByYear":159,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":160,"totalCitation":19,"totalCitationByYear":161,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":162,"hindexLast5Year":19,"hindex":19},{},{"1992":94},{},{},{"volume":164,"pages":166},{"VOID":165},"23",{"VOID":167},"11-25","2000-03-01",2000,false,{"id":172,"createTime":173,"updateTime":173,"relativeEntities":174,"slug":18,"properties":175,"entityType":115,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":182,"fullTextUrl":18,"authors":183,"publicationType":134,"publisherRelationship":214,"citationCount":18,"citationInfo":18,"publishDate":247,"publishYear":248,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":170},"0a8685e9-1dce-4aea-bd3f-9907ae7977a9","2023-12-07T23:57:25.623+00:00",[],{"references":176,"title":178,"doi":180},{"VOID":177},"Adams, K. M., Jacisin, J., Brown, G. G., et al.: Neuropsychological and CT deficits in schizophrenics. Presented at the 133rd Annual APA Meeting, San Francisco, 1980\nCarr, 1984, Neuropsychological assessment of cerebral ventricular size in chronic schizophrenics, Int. J. Clin. Neurol. Psychol., 6, 106\nDeMeyer, 1984, Third ventricle size and ventricular-brain ratio in treatment-resistant psychiatric patients, J. Operational Psychiatry, 15, 2\nDeMeyer, 1984, Brain densities in treatment-resistant schizophrenic and other psychiatric patients, J. Operational Pscyhiatry, 15, 9\nDonnelly, 1980, Cognitive impairment associated with morphological brain abnormalities in computerized tomography in chronic schizophrenic patients, J. Nerv. Ment. Dis., 168, 305, 10.1097\u002F00005053-198005000-00011\nFamuyiwa, 1979, Tardive dyskinesia and dementia, Br. J. Psychiatry, 135, 500, 10.1192\u002Fbjp.135.6.500\nGolden, 1981, The Luria-Nebraska Neuropsychological Battery: Theory and research, Vol. 5, 191\nGolden, 1980, Differentiation of chronic schizophrenia with and without ventricular enlargement by the Luria-Nebraska Neuropsychological Battery, Int. J. Neurosci., 11, 131, 10.3109\u002F00207458009150337\nGolden, 1982, Cross-validation of the ability of the Luria-Nebraska neuropsychological battery to differentiate chronic schizophrenics with and without ventricular enlargement, J. Consult. Clin. Psychol., 50, 87, 10.1037\u002F0022-006X.50.1.87\nGolden, 1980, Cerebral ventricular size and neuropsychological impairment in young chronic schizophrenics, Arch. Gen. Psychiatry, 37, 619, 10.1001\u002Farchpsyc.1980.01780190017001\nHaug, 1962, Pneumoencephalographic studies in mental disease, Acta Psychiatr. Scand., 38, 1\nHuckman, 1975, The validity of criteria for the evaluation of cerebral atrophy by computer tomography, Radiology, 116, 85, 10.1148\u002F116.1.85\nJeringan, 1982, Computer tomography in schizophrenics and normal volunteers, Arch. Gen. Psychiatry, 39, 765, 10.1001\u002Farchpsyc.1982.04290070001001\nJohnstone, 1978, The dementia of dementia praecox, Acta Psychiatr. Scand., 57, 305, 10.1111\u002Fj.1600-0447.1978.tb06899.x\nJohnstone, 1976, Cerebral ventricular size and cognitive impairment in chronic schizophrenia, Lancet, 2, 924, 10.1016\u002FS0140-6736(76)90890-4\nLawson, W. B., Waldman, I. N., and Weinberger, D. R.: Schizophrenic dementia: Results of neuropsychological testing and clinical correlates. Unpublished data\nLuchins, 1982, Computer tomography in schizophrenia: Disparities in the prevalence of abnormalities, Arch. Gen. Psychiatry, 39, 859, 10.1001\u002Farchpsyc.1982.04290070079015\nMaser, 1983, CT scans and schizophrenia: Report on a workshop, Schizophr. Bull., 9, 265, 10.1093\u002Fschbul\u002F9.2.265\nNasrallah, 1982, Cerebral ventricular enlargement in subtypes of chronic schizophrenia, Arch. Gen. Psychiatry, 39, 774, 10.1001\u002Farchpsyc.1982.04290070010003\nNasrallah, 1983, Clinical differences between schizophrenic patients with and without large cerebral ventricles, J. Clin. Psychiatry, 44, 407\nNasrallah, 1983, Clinical correlates in sulcal widening in chronic schizophrenia, Psychiatr. Res., 10, 237, 10.1016\u002F0165-1781(83)90070-7\nNasrallah, 1982, Cortical atrophy in schizophrenia and mania: A comparative CT study, J. Clin. Psychiatry, 43, 439\nOwens, 1985, Lateral ventricular size in schizophrenia: Relationship to the disease process and its clinical manifestations, Psychol. Med., 15, 27, 10.1017\u002FS0033291700020900\nPandurangi, A. K., Dewan, M. J., Boucher, M., et al.: A comprehensive study of chronic schizophrenia: II. Biological subtyping using EEG, platelet MAO, serum DBH, and neuropsychological correlates. Biol. Psychiatry, in press, 1986\nPandurangi, A., Bilder, R., Reider, R., et al.: CT correlates of cognitive deficits in schizophrenia. Presented at the 137th APA Annual Meeting, Los Angeles, 1984\nReider, 1979, Sulcal prominence in young chronic schizophrenic patients: CT scan findings associated with impairment of neuropsychological tests, Psychiatr. Res., 1, 1, 10.1016\u002F0165-1781(79)90021-0\nSeidman, 1983, Schizophrenia and brain dysfunction: An integration of recent neurodi agnostic findings, Psychol. Bull., 94, 195, 10.1037\u002F0033-2909.94.2.195\nWeinberger, 1984, CAT scan findings in schizophrenia: Speculation on the meaning of it all, J. Psychiatr. Res., 13, 477, 10.1016\u002F0022-3956(84)90035-9\nWeinberger, 1986, Clinical-neuropathological correlations in schizophrenia: Theoretical implications\nWeinberger, 1979, Lateral cerebral ventricular enlargement in chronic schizophrenia, Arch. Gen. Psychiatry, 36, 735, 10.1001\u002Farchpsyc.1979.01780070013001\nWeinberger, 1979, Structural abnormalities in the cerebral cortex of chronic schizophrenic patients, Arch. Gen. Psychiatry, 36, 935, 10.1001\u002Farchpsyc.1979.01780090021002\nWeinberger, 1983, Neuropathological studies of schizophrenia: A selective review, Schizophr. Bull., 9, 193, 10.1093\u002Fschbul\u002F9.2.193\nWeinberger, 1982, Cerebral ventricular size: A biological marker for subtyping chronic schizophrenia, 505",{"EN":179},"Relationship Between CT Scan Findings and Neuropsychological Performance in Chronic Schizophrenia",{"VOID":181},"10.1016\u002Fs0193-953x(18)30634-8","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0193953X18306348",[184,199],{"id":185,"sortIndex":94,"researcher":18,"roles":186,"affiliations":187,"properties":196},"20c172d1-fd54-41e8-b249-563806197c45",[122],[188],{"id":18,"sortIndex":19,"affiliation":189,"properties":18},{"id":190,"createTime":191,"updateTime":191,"relativeEntities":192,"slug":18,"properties":193,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"b6589dc9-ef8e-4e9b-b8f9-8ec7d67c9b1d","2023-12-07T23:57:25.650+00:00",[],{"title":194},{"VI":195},"Chief, Clinical Neuropsychiatry and Neurobehavior Section Intramural Research Program, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, D. C.",{"title":197},{"VI":198},"Daniel R. Weinberger",{"id":200,"sortIndex":19,"researcher":18,"roles":201,"affiliations":202,"properties":211},"72997fa3-b015-4b64-80f2-4f1437a46e53",[122],[203],{"id":18,"sortIndex":19,"affiliation":204,"properties":18},{"id":205,"createTime":206,"updateTime":206,"relativeEntities":207,"slug":18,"properties":208,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"98e7d337-3ac6-4421-8579-f02a0d41b8bf","2023-12-07T23:57:25.635+00:00",[],{"title":209},{"VI":210},"Assistant Professor, Andrew McFarland Mental Health Center, and Department of Psychiatry, Southern Illinois University School of Medicine, Springfield, Illinois",{"title":212},{"VI":213},"Ronald F. Zee",{"url":182,"publisher":215,"properties":242},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":216,"slug":10,"properties":217,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":220,"manageAffiliations":221,"indexDatabases":222,"url":18,"thumbnailPath":18,"statistic":237,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":218,"title":219},{"VOID":13},{"EN":15},[],[],[223,230],{"id":55,"indexDatabase":224,"url":68,"indexYears":69,"academicFieldIds":229,"indexDatabaseRanking":72},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":225,"label":226,"description":227,"key":65,"publicationTags":228,"standard":18},[],{"EN":62,"VI":62},{"EN":62,"VI":64},[67],[71],{"id":74,"indexDatabase":231,"url":89,"indexYears":18,"academicFieldIds":236,"indexDatabaseRanking":18},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":232,"label":233,"description":234,"key":85,"publicationTags":235,"standard":18},[],{"EN":81,"VI":81},{"VI":83,"EN":84},[87,88],[91],{"impactFactor":19,"impactFactorByYear":238,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":239,"totalCitation":19,"totalCitationByYear":240,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":241,"hindexLast5Year":19,"hindex":19},{},{"1992":94},{},{},{"volume":243,"pages":245},{"VOID":244},"9",{"VOID":246},"49-61","1986-03-01",1986,{"id":250,"createTime":251,"updateTime":251,"relativeEntities":252,"slug":18,"properties":253,"entityType":115,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":260,"fullTextUrl":18,"authors":261,"publicationType":134,"publisherRelationship":302,"citationCount":18,"citationInfo":18,"publishDate":335,"publishYear":336,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":170},"d8b1d92e-eb96-4526-bd73-8a791cc5aca7","2024-01-10T23:55:34.432+00:00",[],{"references":254,"title":256,"doi":258},{"VOID":255},"Alexanderson, 1969, Steady state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy, Br Med J, 4, 764, 10.1136\u002Fbmj.4.5686.764\nAmsterdam, 1984, Cimetidine-induced alterations in desipramine plasma concentrations, Psychopharmacology, 83, 373, 10.1007\u002FBF00428548\nAnanth, 1977, A review of combined tricyclic and MAOI therapy, Compr Psychiatry, 18, 221, 10.1016\u002F0010-440X(77)90016-5\nArana, 1988, Carbamazepine-induced reduction of plasma alprazolam concentrations: A clinical case report, J Clin Psychiatry, 49, 448\nAranow, 1989, Elevated antidepressant plasma levels after addition of fluoxetine, Am J Psychiatry, 146, 911, 10.1176\u002Fajp.146.7.911\nAustin, 1990, Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients, J Clin Psychiatry, 51, 344\nAyesh, 1988, Influence of quinidine on the pharmacokinetics of nortriptyline and desipramine, Br J Clin Pharmacol, 25, 140\nBaastrup, 1976, Adverse reactions in treatment with lithium carbonate and haloperidol, JAMA, 236, 2645, 10.1001\u002Fjama.1976.03270240041024\nBack, 1990, Pharmacokinetic drug interactions with oral contraceptives, Clin Pharmacokinet, 18, 472, 10.2165\u002F00003088-199018060-00004\nBaldessarini, 1990, Drugs and the treatment of psychiatric disorders, 383\nBaldessarini, 1991, Clozapine: A novel antipsychotic agent, N Engl J Med, 324, 746, 10.1056\u002FNEJM199103143241107\nBaldessarini, 1988, Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs, J Clin Psychopharmacol, 8, 381, 10.1097\u002F00004714-198810000-00026\nBatlle, 1985, Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy, N Engl J Med, 312, 408, 10.1056\u002FNEJM198502143120705\nBeattie, 1988, Verapamil-induced carbamazepine neurotoxicity: A report of 2 cases, Eur Neurol, 28, 104, 10.1159\u002F000116239\nBergstrom, 1990, Drug interaction between fluoxetine and the tricyclic antidepresants imipramine and desipramine, Pharm Res, 7, S254\nBernstein, 1978, Medical-psychiatric drug interactions, 483\nBerridge, 1982, Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands, Biochem J, 206, 587, 10.1042\u002Fbj2060587\nBinder, 1991, Diltiazem-induced psychosis and a possible diltiazem-lithium interaction, Arch Intern Med, 151, 373, 10.1001\u002Farchinte.1991.00400020119023\nBlackwell, 1991, Monoamine oxidase inhibitor interactions with other drugs, J Clin Psychopharmacol, 11, 55, 10.1097\u002F00004714-199102000-00009\nBoakes, 1973, Sympathomimetic amines and antidepresant agents, BMJ, 2, 114, 10.1136\u002Fbmj.2.5858.114-a\nBrosen, 1989, Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine, Eur J Clin Pharmacol, 37, 155, 10.1007\u002FBF00558224\nBrosen, 1991, Fluoxetine and norfluoxetine are potent inhibitors of P450IID6—The source of sparteine\u002Fdebrisoquine oxidation polymorphism, Br J Clin Pharmacol, 36, 136, 10.1111\u002Fj.1365-2125.1991.tb05630.x\nBrosen, 1992, Pharmacogenetics of tricyclic antidepressants and novel antidepressants: Recent developments, Clin Neuropharmacol, 15, 80A, 10.1097\u002F00002826-199201001-00043\nBrown, 1990, Possible influence of carbamazepine on plasma imipramine concentrations in children with attention deficit hyperactivity disorder, J Clin Psychopharmacol, 10, 359\nBrunn, 1988, Lithium clearance and renal tubular sodium handling during acute and long-term nifedipine treatment in essential hypertension, Clin Sei, 75, 609, 10.1042\u002Fcs0750609\nByrd, 1977, Lithium carbonate and methyldopa: Apparent interaction in man, Clin Toxicol, 11, 1, 10.3109\u002F15563657708989812\nCater, 1986, The use of Na+ and K+ to to reduce toxicity and side effects from lithium, Med Hypotheses, 20, 359, 10.1016\u002F0306-9877(86)90097-6\nChaudrey, 1983, Lithium and carbamazepine interaction: Possible neurotoxicity, J Clin Psychiatry, 44, 30\nCiraulo, 1990, Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics, J Clin Psychopharmacol, 10, 48, 10.1097\u002F00004714-199002000-00009\nCiraulo, 1990, Fluoxetine drug-drug interactions: II, J Clin Psychopharmacol, 10, 213\nCiraulo, 1990, Question the experts, J Clin Psychopharmacol, 10, 306, 10.1097\u002F00004714-199008000-00026\nCiraulo, 1988, Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers, Clin Pharmacol Ther, 43, 509, 10.1038\u002Fclpt.1988.66\nCiraulo, 1989\nCobb, 1991, Possible interaction between clozapine and lorazepam, Am J Psychiatry, 148, 1606, 10.1176\u002Fajp.148.11.1606b\nCohen, 1974, Lithium carbonate, haloperidol, and irreversible brain damage, JAMA, 230, 1283, 10.1001\u002Fjama.1974.03240090023018\nCsemansky, 1985, Using lithium in patients with cardiac and renal disease, Hospital Formulary, 20, 726\nCuthbert, 1969, Cough and cold remedies: A potential danger to patients on monoamine oxidase inhibitors, BMJ, 1, 404, 10.1136\u002Fbmj.1.5641.404\nDavis, 1974, Psychopharmacology in the aged. Use of psychotropic drugs in geriatric patients, J Geriatr Psychiatry, 7, 145\nDemers, 1971, Sodium intake and lithium treatment in man, Am J Psychiatry, 128, 100, 10.1176\u002Fajp.128.1.100\nDevane, 1990\nDevane, 1992, Pharmacokinetics of the selective serotonin reuptake inhibitors, J Clin Psychiatry, 53, 13\nDhillon, 1982, Valproic acid and diazepam interaction in vivo, Br J Clin Pharmacol, 13, 553, 10.1111\u002Fj.1365-2125.1982.tb01421.x\nDouste-Blazy, 1986, Angiotensin converting enzyme inhibitors and lithium treatment, Lancet, 1, 1448, 10.1016\u002FS0140-6736(86)91598-9\nEdou, 1983, Interaction medicamenteuse: Clometacin-lithium, Presse Med, 3, 1551\nEichelbaum, 1985, Carbamazepine metabolism in man; induction and pharmacogenetic aspects, Clin Pharmacokinetics, 10, 80, 10.2165\u002F00003088-198510010-00004\nElis, 1967, Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure, BMJ, 2, 75, 10.1136\u002Fbmj.2.5544.75\nEreshefsky, 1986, Bioavaüability of psychotropic drugs: Historical perspective and pharmacokinetic overview, J Clin Psychiatry, 47, 6\nEreshefsky, 1991, Thiothixene pharmacokinetic interactions: A study of hepatic enzyme inducers, clearance inhibitors, and demographic variables, J Clin Psychopharmacol, 11, 296, 10.1097\u002F00004714-199110000-00004\nFann, 1974, Chlorpromazine: Effects of antacids on its gastrointestinal absorption, J Clin Pharmacol, 13, 229\nFrölich, 1979, Indomethacin increases plasma lithium, BMI, 1, 1115\nGadde, 1990, Diltiazem effect on carbamazepine levels in manic depression, J Clin Psychopharmacol, 10, 378, 10.1097\u002F00004714-199010000-00026\nGarbutt, 1987, Potentiation of propoxyphene by phenelzine, Am J Psychiatry, 144, 251, 10.1176\u002Fajp.144.2.251\nGlassman, 1981, Cardiovascular effects of therapeutic doses of tricyclic antide pressants, Arch Gen Psychiatry, 38, 815, 10.1001\u002Farchpsyc.1981.01780320095011\nGodinich, 1990, Renal tubular effects of lithium, Kidney Int, 37, 52\nGoff, 1991, Elevation of plasma concentrations of haloperidol after the addition of fluoxetine, Am J Psychiatiy, 148, 790, 10.1176\u002Fajp.148.6.790\nGoldstein, 1974\nGoodnick, 1991, Pharmacokinetics of second generation antidepressants: Fluoxetine, Psychopharmacol Bull, 27, 503\nGoodnick, 1981, Current topics in lithium treatment, Hosp Formul, 16, 1346\nGoodnick, 1991, Lithium pharmacokinetics, Psychopharmacol Bull, 27, 475\nGoulden, 1987, Clinical valproate toxicity induced by acetylsalicylic acid, Neurology, 37, 1392, 10.1212\u002FWNL.37.8.1392\nGram, 1974, Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man, Am J Psychiatry, 131, 863, 10.1176\u002Fajp.131.8.863\nGreenblatt, 1987, Clonazepam pharmacokinetics brain uptake, and receptor interactions, J Clin Psychiatry, 4, 4\nGreenblatt DJ, Preskom S, Cotreau M: Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol, in press\nGreil, 1985, Lithium dosage in the elderly, J Affective Disord, 9, 1, 10.1016\u002F0165-0327(85)90002-3\nGrimsley, 1992, Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors, Clin Pharmacol, 11, 930\nGrimsley, 1991, Increased carbamazepine plasma concentrations after fluoxetine coadministration, Clin Pharmacol Ther, 50, 10, 10.1038\u002Fclpt.1991.98\nGrohmann, 1989, Adverse effects of clozapine, Psychopharmacology, 99, S101, 10.1007\u002FBF00442571\nGuze, 1992\nHanna, 1990, Severe lithium toxicity associated with indapamide therapy, J Clin Psychopharmacol, 10, 379, 10.1097\u002F00004714-199010000-00027\nHansen, 1971, Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man, Clin Pharmacol Ther, 12, 539, 10.1002\u002Fcpt1971123539\nHansen, 1990, Interaction of fluoxetine and pentazocine, Am J Psychiatry, 147, 949, 10.1176\u002Fajp.147.7.949\nHenhauer, 1984, Cimetidine interaction with imipramine and nortriptyline, Clin Pharmacol Ther, 35, 183, 10.1038\u002Fclpt.1984.24\nHoffman, 1971, Antiarrhythmic drugs, 824\nHowes, 1983, Reduced steady-state plasma concentrations of indomethacin and chlorpromazine in patients receiving Cimetidine, Eur J Clin Pharmacol, 24, 99, 10.1007\u002FBF00613934\nHuang, 1990, Lithium intoxication with coadministration of a loop diuretic, J Clin Psychopharmacol, 10, 228, 10.1097\u002F00004714-199006000-00022\nHurtig, 1974, Lithium toxicity enhanced by diuresis, N Engl J Med, 290, 748, 10.1056\u002FNEJM197403282901324\nJann, 1985, Effects of carbamazepine on haloperidol levels, J Clin Psychopharmacol, 5, 106, 10.1097\u002F00004714-198504000-00010\nJann, 1986, Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance, Psychopharmacology, 90, 468, 10.1007\u002FBF00174062\nJanowsky, 1981, Effects of anesthesia on patients taking psychotropic drugs, J Clin Psychopharmacol, 1, 14, 10.1097\u002F00004714-198101000-00004\nJeavons, 1977, Treatment of generalized epilepsies of childhood and adolescence with sodium valproate, Dev Med Child Neurol, 19, 9, 10.1111\u002Fj.1469-8749.1977.tb08015.x\nJefferson, 1989, Cardiovascular effects and toxicity of anxiolytics and antidepressants, J Clin Psychiatry, 50, 368\nJefferson, 1979, Serum lithium levels and long-term diuretic use, JAMA, 241, 1134, 10.1001\u002Fjama.1979.03290370038025\nJudd, 1990, Pharmacotherapy of panic disorder, Int Rev Psychiatry, 2, 287, 10.3109\u002F09540269009026609\nKahn, 1990, Change in haloperidol level due to carbamazepine—A complicating factor in combined medication for schizophrenia, J Clin Psychopharmacol, 10, 54, 10.1097\u002F00004714-199002000-00011\nKatz, 1991, Raised serum levels of desipramine with the antiarrhythmic propafenone, J Clin Psychiatry, 52, 432\nKerry, 1980, Diuretics are dangerous with lithium, BMJ, 2, 371, 10.1136\u002Fbmj.281.6236.371\nKhoo, 1980, Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonezepam, Clin Pharmacol Ther, 28, 368, 10.1038\u002Fclpt.1980.175\nKramer, 1986, Carbamazepine-danazol interaction: Its mechanism examined by a stable isotope technique, Ther Drug Monit, 8, 387, 10.1097\u002F00007691-198612000-00001\nLafferman, 1988, Lithium augmentation for treatment-resistant depression in the elderly, J Geriatr Psychiatry Neurol, 1, 49, 10.1177\u002F089198878800100109\nLai, 1978, Time-course of interaction between carbamazepine and clonazepam in man, Clin Pharmacol Ther, 24, 316, 10.1002\u002Fcpt1978243316\nLeinonen, 1991, Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients, J Clin Psychopharmacol, 11, 313, 10.1097\u002F00004714-199110000-00007\nLeishman, 1963, Antagonism of guanethidine by imipramine, Lancet, 1, 112, 10.1016\u002FS0140-6736(63)91123-1\nLemberger, 1985, Fluoxetine: Clinical pharmacology and physiologic disposition, J Clin Psychiatry, 46, 14\nLemberger, 1988, The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam, Clin Pharmacol Ther, 43, 412, 10.1038\u002Fclpt.1988.52\nLinnoila, 1982, Interaction between antidepressants and perphenazinein psychiatric inpatients, Am J Psychiatry, 139, 1329, 10.1176\u002Fajp.139.10.1329\nLinnoila, 1980, Effect of anticonvulsants on plasma haloperidol and thioridazine levels, Am J Psychiatry, 137, 7\nLipinski, 1982, Possible synergistic action between carbamazepine and lithium carbonate in the treatment of three acutely manic patients, Am J Psychiatry, 139, 948, 10.1176\u002Fajp.139.7.948\nLock, 1990, Possible adverse drug interactions between fluoxetine and other psychotropics, J Clin Psychopharmacol, 10, 383, 10.1097\u002F00004714-199010000-00031\nLoga, 1981, Interaction of chlorpromazine and nortriptyline in patients with schizophrenia, Clin Pharmacokinet, 6, 454, 10.2165\u002F00003088-198106060-00003\nMacLoed, 1978, Interaction of disulfiram with benzodiazepines, Clin Pharmacol Ther, 24, 583, 10.1002\u002Fcpt1978245583\nMallinger, 1991, Pharmacokinetics of monoamine oxidase inhibitors, Psychopharmacol Bull, 27, 493\nMarley, 1984, Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine, or noradrenaline reuptake, J Psychiatr Res, 18, 173, 10.1016\u002F0022-3956(84)90008-6\nMay, 1985, Serum concentrations of valproic acid: Influence of dose and comedication, Ther Drug Monit, 7, 387, 10.1097\u002F00007691-198512000-00004\nMcElroy, 1971, Valproate in psychiatric disorders: Literature review and clinical guidelines, J Clin Psychiatry, 50, 23\nMcGinness, 1990, Avoiding neurotoxicity with lithiumcarbamazepine combinations, Psychopharmacol Bull, 26, 181\nMcGrath, 1992, Preliminary information about sertraline (Zoloft)—A new, highly selective, serotonin reuptake-inhibitor, Currents in Affective Illness, 11, 5\nMiller, 1990, Cigarettes and drug therapy: Pharmacokinetic and pharmacodynamic considerations, Clin Pharmacol, 9, 125\nMurray, 1992, P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease, Clin Pharmacokinet, 23, 132, 10.2165\u002F00003088-199223020-00005\nMyers, 1990, Plasma and erythrocyte lithium concentrations before and after oral verapamil, Lithium, 1, 49\nNebert, 1991, The P450 superfamily: Update on new sequences, gene mapping and recommended nomenclature, DNA Cell Biol, 10, 1, 10.1089\u002Fdna.1991.10.1\nNelson JC: Blood level monitoring of antidepressant and antipsychotic drugs: How useful is it? Psychiatric Times, October 1992, pp 20–26\nNelson, 1980, Neuroleptic effect on desipramine steady-state plasma concentrations, Am J Psychiatry, 137, 1232, 10.1176\u002Fajp.137.10.1232\nNelson, 1982, Major adverse reactions during desipramine treatment, relationship to plasma drug concentrations, concomitant antipsychotic treatment, and patient characteristics, Arch Gen Psychiatry, 39, 1055, 10.1001\u002Farchpsyc.1982.04290090045010\nNoveske, 1989, Possible toxicity of combined fluoxetine and lithium, Am J Psychiatry, 146, 1515, 10.1176\u002Fajp.146.11.1515a\nOchs, 1981, Diazepam interaction with antituberculous drugs, Clin Pharmacol Ther, 29, 671, 10.1038\u002Fclpt.1981.94\nOh, 1977, Furosemide and lithium toxicity, Anaesth Intensive Care, 5, 60, 10.1177\u002F0310057X7700500110\nOrr, 1982, Interaction between valproic acid in epileptic children: Serum protein binding and metabolic effects, Clin Pharmacol Ther, 31, 642, 10.1038\u002Fclpt.1982.89\nPatel, 1980, Phenobarbital-valproic acid interaction, Clin Pharmacol Ther, 27, 515, 10.1038\u002Fclpt.1980.72\nPatwardhan, 1983, Differential effects of oral contraceptive steroids on the metabolism of benzodiazepines, Hepatology, 3, 248, 10.1002\u002Fhep.1840030219\nPearson, 1990, Interaction of fluoxetine with carbamazepine, J Clin Psychiatry, 51, 126\nPerei, 1975, Pharmacodynamics of imipramine in depressed patients, Psychopharmacol Bull, 11, 16\nPerei, 1969, Inhibitiion of imipramine metabolism by methylphenidate, Federation Proceedings, 28, 418\nPerry, 1986, Effects of smoking on nortriptyline plasma concentrations in depressed patients, Ther Drug Monit, 8, 279, 10.1097\u002F00007691-198609000-00007\nPerry, 1984, Theophylline precipitated alterations in lithium clearance, Acta Psychiatr Scand, 69, 528, 10.1111\u002Fj.1600-0447.1984.tb02527.x\nPetersen, 1974, Effect of prolonged thiazide treatment on renal lithium clearance, BMJ, 2, 143, 10.1136\u002Fbmj.3.5924.143\nPhillips, 1986, A pharmacokinetic interaction between erythromycin and triazolam, J Clin Psychopharmacol, 6, 297, 10.1097\u002F00004714-198610000-00008\nPope, 1988, Possible synergism between fluoxetine and lithium in refractory depression, Am J Psychiatry, 145, 1292, 10.1176\u002Fajp.145.10.1292\nPost, 1987, Correlates of antimanic response to carbamazepine, Psychiatry Res, 21, 71, 10.1016\u002F0165-1781(87)90064-3\nPrakash, 1982, Neurotoxicity with combined administration of lithium with a neuroleptic, Compr Psychiatry, 23, 567, 10.1016\u002F0010-440X(82)90049-9\nPreskom, 1982, Toxicity of tricyclic antidepressants: Kinetics, mechanism, intervention: A review, J Clin Psychiatry, 43, 151\nPreskom SH, Alderman J, Chung M, et al: Desipramine levels after sertraline or fluoxetine. Presented at the 145th annual meeting of the American Psychiatric Association, May 2–7, 1992, Washington\nPrice, 1986, Neruotoxicity caused by lithium-verapamil synergism, J Clin Pharmacol, 26, 717, 10.1002\u002Fj.1552-4604.1986.tb02980.x\nRagheb, 1981, Drug interactions in psychiatric practice, Int Pharmacopsychiatry, 16, 92, 10.1159\u002F000468482\nRagheb, 1987, Ibuprofen can increase serum lithium level in lithium-treated patients, J Clin Psychiatry, 48, 161\nRagheb, 1990, The interaction of lithium with phenylbutazone in bipolar affective patients, J Clin Psychopharmacol, 10, 149, 10.1097\u002F00004714-199004000-00030\nRagheb, 1986, Lithium interaction with sulindac and naproxen, J Clin Psychopharmacol, 6, 150, 10.1097\u002F00004714-198606000-00005\nReimann, 1981, Effect of diclofenac on lithium kinetics, Clin Pharmacol Ther, 30, 348, 10.1038\u002Fclpt.1981.171\nReimann, 1983, Indomethacin but not aspirin increases plasma lithium ion levels, Arch Gen Psychiatry, 40, 283, 10.1001\u002Farchpsyc.1983.01790030053006\nRisch, 1981, Interfaces of psychopharmacology and cardiology, pt 1, J Clin Psychiatry, 42, 23\nRisch, 1981, Interfaces of psychopharmacology and cardiology, pt 2, J Clin Psychiatry, 42, 47\nRivera-Calimlim, 1978, Effect of lithium on plasma chlorpromazine levels, Clin Pharmacol Ther, 23, 451, 10.1002\u002Fcpt1978234451\nRivers, 1970, Possible lethal reaction between Nardil and dextromethorphan, Can Med Assoc J, 103, 85\nRosenblatt, 1992, More about spontaneous postmarketing reports of bupropion-related seizures, Currents in Affective Illness, 11, 18\nSaffer, 1983, Furosemide: A safe diuretic during lithium therapy?, J Affective Disord, 5, 289, 10.1016\u002F0165-0327(83)90017-4\nSalama, 1989, A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate, Am J Psychiatry, 146, 278, 10.1176\u002Fajp.146.2.278a\nSchou, 1990, Lithium and treatment-resistant depressions: A review, Lithium, 1, 3\nSchwarcz, 1982, The problem of antihypertensive treatment in lithium patients, Compr Psychiatry, 23, 50, 10.1016\u002F0010-440X(82)90008-6\nSellers, 1982, Benzodiazepines and ethanol: Assessment of the effects and consequences of psychotropic drug interactions, J Clin Psychopharmacol, 2, 249, 10.1097\u002F00004714-198208000-00004\nShoaf, 1991, The interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications, Psychopharmacol Bull, 27, 577\nShopsin, 1973, Iodine and lithium-induced hypothyroidism. Documentation of synergism, Am J Med, 55, 695, 10.1016\u002F0002-9343(73)90193-9\nSierles, 1982, Concurrent use of theophylline and lithium in a patient with chronic obstructive lung disease and bipolar disorder, Am J Psychiatry, 139, 117, 10.1176\u002Fajp.139.1.117\nSilver, 1986, Elevation of thioridazine levels by propranolol, Am J Psychiatry, 143, 1290, 10.1176\u002Fajp.143.10.1290\nShulman, 1989, Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors, J Clin Psychopharmacol, 9, 397, 10.1097\u002F00004714-198912000-00002\nSovner, 1991, A potential drug interaction between fluoxetine and valproic acid, J Clin Psychopharmacol, 11, 389, 10.1097\u002F00004714-199112000-00018\nSpring, 1979, Neurotoxicity with combined use of lithium and thioridazine, J Clin Psychiatry, 40, 135\nSteiner, 1986, Toxic reaction following the combined administration of fluoxetine and L-tryptophan: Five case reports, Biol Psychiatry, 21, 1067, 10.1016\u002F0006-3223(86)90287-8\nStembach, 1988, Danger of MAOI therapy after fluoxetine withdrawal, Lancet, 2, 850, 10.1016\u002FS0140-6736(88)92812-7\nStembach, 1991, Fluoxetine-associated potentiation of calcium-channel blockers, J Clin Psychopharmacol, 11, 390, 10.1097\u002F00004714-199112000-00019\nStoeh, 1984, Effect of oral contraceptives on triazolam, temazepam, alprazolam and lorazepam kinetics, Clin Pharmacol Ther, 36, 683, 10.1038\u002Fclpt.1984.240\nTate, 1989, Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine, Am J Psychiatry, 146, 399, 10.1176\u002Fajp.146.3.399b\nTeas, 1981, Toxic delirium resulting from combination antidepressant therapy, Am J Psychiatry, 138, 1127, 10.1176\u002Fajp.138.8.1127a\nTesar, 1985, Use of high-dose intravenous haloperiodol in the treatment of agitated cardiac patients, J Clin Psychopharmacol, 5, 344, 10.1097\u002F00004714-198505060-00009\nTesar, 1991, Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder, J Clin Psychiatry, 52, 68\nThomsen, 1968, Renal lithium excretion in man, Am J Physiol, 215, 823, 10.1152\u002Fajplegacy.1968.215.4.823\nTyndale, 1991, Oxidation of reduced haloperidol to haloperidol: Involvement of human P450IID6, Br J Pharmacol, 31, 655, 10.1111\u002Fj.1365-2125.1991.tb05588.x\nVan Spanning, 1973, The interference of tricyclic antidepressants with the central hypotensive effect of clonidine, Eur J Pharmacol, 24, 402, 10.1016\u002F0014-2999(73)90169-6\nVaughan, 1988, Interaction of fluoxetine with tricyclic antidepressants, Am J Psychiatry, 145, 1478, 10.1176\u002Fajp.145.11.1478b\nVigran, 1964, Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride, JAMA, 187, 953, 10.1001\u002Fjama.1964.03060250071021\nvon Ammon Cavanaugh, 1990, Drug-drug interactions of fluoxetine with tricyclics, Psychosomatics, 31, 273, 10.1016\u002FS0033-3182(90)72163-9\nWalbridge, 1985, An interaction between lithium carbonate and piroxicam presenting as lithium toxicity, Br J Psychiatry, 147, 206, 10.1192\u002Fbjp.147.2.206\nWalker, 1980, Lithium-methyldopa interactions in normal subjects, Drug Intelligence and Clinical Pharmacy, 14, 638\nWames, 1976, Adynamic ileus during p>sychoactive medication, Can Med Assoc J, 96, 1112\nWeilburg, 1989, Fluoxetine added to non-MAOI antidepressants converts non-responders to responders: A preliminary report, J Clin Psychiatry, 50, 447\nWeinrauch, 1984, Decreased serum lithium during verapamil therapy, Am Heart J, 108, 1378, 10.1016\u002F0002-8703(84)90776-2\nWhite, 1986, Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril, Arch Intern Med, 146, 1833, 10.1001\u002Farchinte.1986.00360210229035\nWilder, 1978, Valproic acid: Interaction with other anticonvulsant drugs, Neurology, 28, 892, 10.1212\u002FWNL.28.9.892\nWong, 1983, Effect of erythromycin on carbamazepine kinetics, Clin Pharmacol Ther, 33, 460, 10.1038\u002Fclpt.1983.62\nWright, 1982, Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction, N Engl J Med, 307, 1325, 10.1056\u002FNEJM198211183072107",{"EN":257},"Drug Interactions in Psychopharmacology",{"VOID":259},"10.1016\u002Fs0193-953x(18)30168-0","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0193953X18301680",[262,278,290],{"id":263,"sortIndex":264,"researcher":18,"roles":265,"affiliations":266,"properties":275},"e647529e-af43-4118-8fad-8d7b365f3ab3",2,[122],[267],{"id":18,"sortIndex":19,"affiliation":268,"properties":18},{"id":269,"createTime":270,"updateTime":270,"relativeEntities":271,"slug":18,"properties":272,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"f9ef2afb-3934-422e-ad32-35b3af24872f","2024-01-10T23:55:34.463+00:00",[],{"title":273},{"VI":274},"From the Department of Psychiatry, Harvard Medical School; and the Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, Massachusetts",{"title":276},{"VI":277},"Jerrold F. Rosenbaum",{"id":279,"sortIndex":19,"researcher":18,"roles":280,"affiliations":281,"properties":287},"b52db3df-40e0-4a41-aa88-872a735b67b2",[122],[282],{"id":18,"sortIndex":19,"affiliation":283,"properties":18},{"id":269,"createTime":270,"updateTime":270,"relativeEntities":284,"slug":18,"properties":285,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":286},{"VI":274},{"title":288},{"VI":289},"Ann M. Callahan",{"id":291,"sortIndex":94,"researcher":18,"roles":292,"affiliations":293,"properties":299},"0fc08f48-4df2-4a79-abe3-59b90eb58b24",[122],[294],{"id":18,"sortIndex":19,"affiliation":295,"properties":18},{"id":269,"createTime":270,"updateTime":270,"relativeEntities":296,"slug":18,"properties":297,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":298},{"VI":274},{"title":300},{"VI":301},"Maurizio Fava",{"url":260,"publisher":303,"properties":330},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":304,"slug":10,"properties":305,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":308,"manageAffiliations":309,"indexDatabases":310,"url":18,"thumbnailPath":18,"statistic":325,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":306,"title":307},{"VOID":13},{"EN":15},[],[],[311,318],{"id":55,"indexDatabase":312,"url":68,"indexYears":69,"academicFieldIds":317,"indexDatabaseRanking":72},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":313,"label":314,"description":315,"key":65,"publicationTags":316,"standard":18},[],{"EN":62,"VI":62},{"EN":62,"VI":64},[67],[71],{"id":74,"indexDatabase":319,"url":89,"indexYears":18,"academicFieldIds":324,"indexDatabaseRanking":18},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":320,"label":321,"description":322,"key":85,"publicationTags":323,"standard":18},[],{"EN":81,"VI":81},{"VI":83,"EN":84},[87,88],[91],{"impactFactor":19,"impactFactorByYear":326,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":327,"totalCitation":19,"totalCitationByYear":328,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":329,"hindexLast5Year":19,"hindex":19},{},{"1992":94},{},{},{"volume":331,"pages":333},{"VOID":332},"16",{"VOID":334},"647-671","1993-09-01",1993,{"id":338,"createTime":339,"updateTime":340,"relativeEntities":341,"slug":342,"properties":343,"entityType":115,"verifyStatus":350,"verifyTime":340,"verifyNote":351,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":352,"fullTextUrl":18,"authors":353,"publicationType":134,"publisherRelationship":398,"citationCount":18,"citationInfo":18,"publishDate":431,"publishYear":432,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":170},"3df1763b-2d37-4cbb-abaa-e4982723cb03","2024-01-12T17:33:20.183+00:00","2025-02-10T23:54:53.804+00:00",[],"Pharmacogenetics-and-Schizophrenia",{"references":344,"title":346,"doi":348},{"VOID":345},"Craddock, 2005, The genetics of schizophrenia and bipolar disorder: dissecting psychosis, J Med Genet, 42, 193, 10.1136\u002Fjmg.2005.030718\nKirov, 2005, Finding schizophrenia genes, J Clin Invest, 115, 1440, 10.1172\u002FJCI24759\nLane, 2005, Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics, Pharmacogenomics, 6, 139, 10.1517\u002F14622416.6.2.139\nMalhotra, 2004, Pharmacogenetics of psychotropic drug response, Am J Psychiatry, 161, 780, 10.1176\u002Fappi.ajp.161.5.780\nKirchheiner, 2004, Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Mol Psychiatry, 9, 442, 10.1038\u002Fsj.mp.4001494\nBishop, 2004, Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response, Pharmacogenomics, 5, 463, 10.1517\u002F14622416.5.5.463\nRoses, 2004, Pharmacogenetics and drug development: the path to safer and more effective drugs, Nat Rev Genet, 5, 645, 10.1038\u002Fnrg1432\nAitchison, 2005, Psychiatry and the “new genetics”: hunting for genes for behaviour and drug response, Br J Psychiatry, 186, 91, 10.1192\u002Fbjp.186.2.91\nLopez-Garcia, 2006, Association between clozapine-induced agranulocytosis and HLA subtyping, J Clin Psychiatry, 67, 1652, 10.4088\u002FJCP.v67n1024e\nPouzet, 2002, Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia, Pharmacol Biochem Behav, 71, 635, 10.1016\u002FS0091-3057(01)00743-2\nJablensky, 2004, Resolving schizophrenia's CATCH22, Nat Genet, 36, 674, 10.1038\u002Fng0704-674\nMeltzer, 1999, The role of serotonin in antipsychotic drug action, Neuropsychopharmacology, 21, 106, 10.1016\u002FS0893-133X(99)00046-9\nItokawa, 1996, Sequestration of the short and long isoforms of dopamine D2 receptors expressed in Chinese hamster ovary cells, Mol Pharmacol, 49, 560\nSchafer, 2001, Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene, Am J Psychiatry, 158, 802, 10.1176\u002Fappi.ajp.158.5.802\nDubertret, 2004, The 3′ region of the DRD2 gene is involved in genetic susceptibility to schizophrenia, Schizophr Res, 67, 75, 10.1016\u002FS0920-9964(03)00220-2\nArinami, 1997, A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia, Hum Mol Genet, 6, 577, 10.1093\u002Fhmg\u002F6.4.577\nJonsson, 1999, Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers, Mol Psychiatry, 4, 290, 10.1038\u002Fsj.mp.4000532\nWu, 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients, Neurosci Lett, 376, 1, 10.1016\u002Fj.neulet.2004.11.014\nParsons, 2004, Association of a D2 receptor gene polymorphism with schizophrenia and treatment response in the Basque and Spanish populations, Am J Med Genet [B], 130, 164\nYamanouchi, 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone, Pharmacogenomics J, 3, 356, 10.1038\u002Fsj.tpj.6500211\nKay, 1987, The Positive and Negative Syndrome Scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093\u002Fschbul\u002F13.2.261\nReynolds, 2005, Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response, Eur Neuropsychopharmacol, 15, 143, 10.1016\u002Fj.euroneuro.2004.07.001\nLencz, 2006, DRD2 promoter region as a predictor of sustained response to antipsychotic medication in first episode schizophrenia patients, Am J Psychiatry, 163, 529, 10.1176\u002Fappi.ajp.163.3.529\nLane, 2004, Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function, Int J Neuropsychopharmacol, 7, 461, 10.1017\u002FS1461145704004389\nKapur, 2001, Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis, Am J Psychiatry, 158, 360, 10.1176\u002Fappi.ajp.158.3.360\nArranz, 1995, Association between clozapine response and allelic variation in 5_HT2A receptor gene, Lancet, 346, 281, 10.1016\u002FS0140-6736(95)92168-0\nLane, 2002, Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene, Am J Psychiatry, 159, 1593, 10.1176\u002Fappi.ajp.159.9.1593\nPolesskaya, 2002, Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics, J Neurosci Res, 67, 812, 10.1002\u002Fjnr.10173\nEllingrod, 2003, 5-HT2A receptor promoter polymorphism, -1438G\u002FA and negative symptom response to olanzapine in schizophrenia, Psychopharmacol Bull, 37, 109\nEllingrod, 2002, 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia, J Clin Psychopharmacol, 22, 622, 10.1097\u002F00004714-200212000-00014\nDavies, 2006, Pharmacologic analysis of non synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotics and agonist efficacies, Pharmacogenomics J, 6, 42, 10.1038\u002Fsj.tpj.6500342\nReynolds, 2005, The role of 5HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment, Prog Neuropsychopharmacol Biol Psychiatry, 29, 1021, 10.1016\u002Fj.pnpbp.2005.03.019\nLane, 2004, Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounds, Schizophr Res, 67, 63, 10.1016\u002Fj.schres.2003.08.006\nOtano, 1999, Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine6 receptors in rat nucleus accumbens by antisense oligonucleotides, Neuroscience, 92, 1001, 10.1016\u002FS0306-4522(99)00066-4\nMeneses, 2001, Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation, Behav Brain Res, 118, 107, 10.1016\u002FS0166-4328(00)00316-8\nMalhotra, 1998, A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics, Mol Psychiatry, 3, 328, 10.1038\u002Fsj.mp.4000412\nOverall, 1962, The brief psychiatric rating scale, Psychol Rep, 10, 799, 10.2466\u002Fpr0.1962.10.3.799\nFromm, 2004, Importance of P-glycoprotein at blood-tissue barriers, Trends Pharmacol Sci, 25, 423, 10.1016\u002Fj.tips.2004.06.002\nMarzolini, 2004, Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance, Clin Pharmacol Ther, 75, 13, 10.1016\u002Fj.clpt.2003.09.012\nHoffmeyer, 2000, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo, Proc Natl Acad Sci U S A, 97, 3473, 10.1073\u002Fpnas.97.7.3473\nTanabe, 2001, Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene, J Pharmacol Exp Ther, 297, 1137\nWoodahl, 2004, The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function, Curr Drug Metab, 5, 11, 10.2174\u002F1389200043489108\nWang, 2004, Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals, Neuropsychopharmacology, 29, 551, 10.1038\u002Fsj.npp.1300372\nDoran, 2005, The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A\u002F1B knockout mouse model, Drug Metab Dispos, 33, 165, 10.1124\u002Fdmd.104.001230\nBoulton, 2002, In vitro P-glycoprotein affinity for atypical and conventional antipsychotics, Life Sci, 71, 163, 10.1016\u002FS0024-3205(02)01680-6\nLin, 2006, The relationship between P-glycoprotein (PGP) and response to olanzapine treatment in schizophrenia, Ther Drug Monit, 28, 668, 10.1097\u002F01.ftd.0000246761.82377.a6\nBlundell, 1984, Serotonin and appetite, Neuropharmacology, 23, 1537, 10.1016\u002F0028-3908(84)90098-4\nLiebowitz, 1990, Anxiety and depression: discrete diagnostic entities?, J Clin Psychopharmacol, 10, 61S, 10.1097\u002F00004714-199006001-00012\nWurtman, 1993, Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers, Neuropsychopharmacology, 9, 201, 10.1038\u002Fnpp.1993.56\nDavis, 1996, Dexfenfluramine. An updated review of its therapeutic use in the management of obesity, Drugs, 52, 696, 10.2165\u002F00003495-199652050-00007\nTecott, 1995, Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors, Nature, 374, 542, 10.1038\u002F374542a0\nMorimoto, 1999, Involvement of the histaminergic system in leptin-induced suppression of food intake, Physiol Behav, 67, 679, 10.1016\u002FS0031-9384(99)00123-7\nBaptista, 1999, Body weight gain induced by antipsychotic drugs: mechanisms and management, Acta Psychiatr Scand, 100, 3, 10.1111\u002Fj.1600-0447.1999.tb10908.x\nReynolds, 2002, Association of antipsychotic induced weight gain with a 5HT2 receptor gene polymorphism, Lancet, 359, 2086, 10.1016\u002FS0140-6736(02)08913-4\nBasile, 2002, Serotonin 2C receptor gene and clozapine-induced weight gain, Lancet, 360, 1790, 10.1016\u002FS0140-6736(02)11706-5\nTsai, 2002, 759C\u002FT genetic variation of 5HT2c receptor and clozapine-induced weight gain, Lancet, 360, 1790, 10.1016\u002FS0140-6736(02)11705-3\nReynolds, 2003, Clozapine-induced weight gain associated with a polymorphism of the promotor region of the 5-HT2C receptor gene, Am J Psychiatry, 160, 677, 10.1176\u002Fappi.ajp.160.4.677\nEllingrod, 2005, Weight gain associated with the -759 C\u002FT polymorphism of the 5HT2C receptor and olanzapine, Am J Med Genet B Neuropsychiatr Genet, 134, 76, 10.1002\u002Fajmg.b.20169\nMiller, 2005, Clozapine-induced weight gain associated with the 5HT2C receptor -759C\u002FT polymorphism, Am J Med Genet B Neuropsychiatr Genet, 133, 97, 10.1002\u002Fajmg.b.30115\nBuckland, 2005, Low gene expression conferred by association of an allele of the 5HT2c receptor gene with antipsychotic-induced weight gain, Am J Psychiatry, 162, 613, 10.1176\u002Fappi.ajp.162.3.613\nTempleman, 2005, Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis, Pharmacogenet Genomics, 15, 195, 10.1097\u002F01213011-200504000-00002\nBasile, 2001, Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle, J Clin Psychiatry, 62, 45\nMiller, 2005, Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial, Schizophr Res, 80, 33, 10.1016\u002Fj.schres.2005.07.034\nMeshul, 1989, Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment, Brain Res, 489, 338, 10.1016\u002F0006-8993(89)90867-6\nZai CC, Hwang RW, De Luca V, et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol; Published online. Cambridge, UK: Cambridge University Press; September 7, 2006.\nGuy, 1976, Abnormal involuntary movement scale, 534\nBadri, 1996, Dopamine and serotonin system genes may predict clinical response to clozapine. In: Proceedings of the 46th Annual Meeting of the American Society of Human Genetics, Am J Hum Genet, 59, A247\nSteen, 1997, Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients, Mol Psychiatry, 2, 139, 10.1038\u002Fsj.mp.4000249\nBasile, 1999, Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia, Neuropsychopharmacology, 21, 17, 10.1016\u002FS0893-133X(98)00114-6\nSegman, 1999, Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia, Mol Psychiatry, 4, 247, 10.1038\u002Fsj.mp.4000511\nLiao, 2001, Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients, Neuropsychobiology, 44, 95, 10.1159\u002F000054924\nLovlie, 2000, Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients, Int J Neuropsychopharmacol, 3, 61, 10.1017\u002FS1461145700001796\nWoo, 2002, Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics, Psychiatry Clin Neurosci, 56, 469, 10.1046\u002Fj.1440-1819.2002.01038.x\nLerer, 2002, Pharmacogenetics of tardive dyskinesia. Combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism, Neuropsychopharmacology, 27, 105, 10.1016\u002FS0893-133X(02)00293-2\nde Leon, 2005, Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness, J Clin Psychopharmacol, 25, 448, 10.1097\u002F01.jcp.0000177546.34799.af\nInada, 1997, Search for a susceptibility locus to tardive dyskinesia, Hum Psychopharmacol Clin Exp, 12, 35, 10.1002\u002F(SICI)1099-1077(199701\u002F02)12:1\u003C35::AID-HUP828>3.0.CO;2-#\nRietschel, 2000, Dopamine D3 receptor variant and tardive dyskinesia, Eur Arch Psychiatry Clin Neurosci, 250, 31, 10.1007\u002FPL00007536\nGarcia-Barcelo, 2001, Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients, J Neural Transm, 108, 671, 10.1007\u002Fs007020170044\nPotkin, 2002, Combining brain imaging and pharmacogenetics in understanding clinical response in Alzheimer's disease and schizophrenia\nSrivastava, 2006, Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV role of dopaminergic pathway gene polymorphisms, Pharmacogenet Genomics, 16, 111, 10.1097\u002F01.fpc.0000184957.98150.0f\nSegman, 2001, Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia, Mol Psychiatry, 6, 225, 10.1038\u002Fsj.mp.4000842\nTan, 2001, Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor, Biol Psychiatry, 50, 144, 10.1016\u002FS0006-3223(01)01076-9\nLerer, 2005, Combined analysis of 635 patients confirms an age related association of serotonin 2A receptor gene with tardive dyskinesia and specificity for non-orofacial subtype, Int J Neuropsychopharmacol, 8, 411, 10.1017\u002FS1461145705005389\nBasile, 2001, Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia, Mol Psychiatry, 6, 230, 10.1038\u002Fsj.mp.4000847\nZhang, 2002, Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia, Mol Psychiatry, 7, 670, 10.1038\u002Fsj.mp.4001052\nIngelman-Sundberg, 2004, Pharmacogenetics of cytochrome P450 and its applications to drug therapy: the past, the present and the future, Trends Pharmacol Sci, 25, 3, 10.1016\u002Fj.tips.2004.02.007\nDe Leon, 2006, Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19, Psychosomatics, 47, 75, 10.1176\u002Fappi.psy.47.1.75\nBradford, 2002, CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants, Pharmacogenomics, 3, 229, 10.1517\u002F14622416.3.2.229\nKapitany, 1998, Genetic polymorphism for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia, Schizophr Res, 32, 101, 10.1016\u002FS0920-9964(98)00038-3\nOhmori, 1998, Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics, Schizophr Res, 32, 107, 10.1016\u002FS0920-9964(98)00018-8\nEllingrod, 2000, Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score, Psychiatr Genet, 10, 9, 10.1097\u002F00041444-200010010-00002\nKirch, 1988, Hypothesis: a nicotine dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia, Cell Mol Neurobiol, 8, 285, 10.1007\u002FBF00711170\nYassa, 1987, Nicotine exposure and tardive dyskinesia, Biol Psychiatry, 22, 67, 10.1016\u002F0006-3223(87)90131-4\nMiller, 1990, The influence of cigarette smoking on haloperidol pharmacokinetics, Biol Psychiatry, 28, 529, 10.1016\u002F0006-3223(90)90488-N\nEllingrod, 2002, Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6, Pharmacotherapy, 22, 1416, 10.1592\u002Fphco.22.16.1416.33700\nSachse, 1997, Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences, Am J Hum Genet, 60, 284\nBasile, 2000, A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia, Mol Psychiatry, 5, 410, 10.1038\u002Fsj.mp.4000736\nSchulze, 2001, Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia, Am J Med Genet, 105, 498, 10.1002\u002Fajmg.1472\nSerretti, 2005, The influence of serotonin transporter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments, Prog Neuropsychopharmacol Biol Psychiatry, 29, 1074, 10.1016\u002Fj.pnpbp.2005.03.013\nBlasi, 2006, Imaging genomics and response to treatment with antipsychotics in schizophrenia, NeuroRx, 3, 117, 10.1016\u002Fj.nurx.2005.12.001\nBertolino, 2004, Interaction of COMT Val108\u002F158Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia, Am J Psychiatry, 10, 1798, 10.1176\u002Fappi.ajp.161.10.1798\nChou, 2000, Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness, J Clin Psychopharmacol, 20, 246, 10.1097\u002F00004714-200004000-00019\nPerlis, 2005, Pharmacogenetic testing in the clinical management of schizophrenia, a decision analytic model, J Clin Psychopharmacol, 25, 427, 10.1097\u002F01.jcp.0000177553.59455.24",{"EN":347},"Pharmacogenetics and Schizophrenia",{"VOID":349},"10.1016\u002Fj.psc.2007.04.004","VERIFIED","Auto Verify","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0193953X07000512",[354,369,386],{"id":355,"sortIndex":94,"researcher":18,"roles":356,"affiliations":357,"properties":366},"b1393c1f-79fc-4fbf-af2d-793e0c83891c",[122],[358],{"id":18,"sortIndex":19,"affiliation":359,"properties":18},{"id":360,"createTime":361,"updateTime":361,"relativeEntities":362,"slug":18,"properties":363,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"77ec5292-2fe7-4f42-927b-9b5cc803f0b2","2024-01-12T17:33:20.233+00:00",[],{"title":364},{"VI":365},"University of Iowa, Carver College of Medicine, Psychiatry Research, #2-105 Medical Education Building, 500 Newton Rd., Iowa City, IA 52242-1000, USA",{"title":367},{"VI":368},"Del D. Miller",{"id":370,"sortIndex":19,"researcher":18,"roles":371,"affiliations":372,"properties":383},"d5ceaff8-19e1-4e4c-a33e-66735535e172",[122],[373],{"id":18,"sortIndex":19,"affiliation":374,"properties":18},{"id":375,"createTime":376,"updateTime":377,"relativeEntities":378,"slug":379,"properties":380,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"bcbb9fa9-2776-4434-b386-676ae9d731a7","2023-12-25T09:12:22.766+00:00","2024-10-01T16:42:03.124+00:00",[],"Department-of-Psychiatry-and-Health-Behavior-Medical-College-of-Georgia-1515-Pope-Avenue-Augusta-GA-30912-USA",{"title":381},{"VI":382},"Department of Psychiatry and Health Behavior, Medical College of Georgia, 1515 Pope Avenue, Augusta, GA 30912, USA",{"title":384},{"VI":385},"Adriana Foster",{"id":387,"sortIndex":264,"researcher":18,"roles":388,"affiliations":389,"properties":395},"eb6df1d9-8753-40d0-85bb-ca9dbf03aa9b",[122],[390],{"id":18,"sortIndex":19,"affiliation":391,"properties":18},{"id":375,"createTime":376,"updateTime":377,"relativeEntities":392,"slug":379,"properties":393,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":394},{"VI":382},{"title":396},{"VI":397},"Peter F. Buckley",{"url":352,"publisher":399,"properties":426},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":400,"slug":10,"properties":401,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":404,"manageAffiliations":405,"indexDatabases":406,"url":18,"thumbnailPath":18,"statistic":421,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":402,"title":403},{"VOID":13},{"EN":15},[],[],[407,414],{"id":55,"indexDatabase":408,"url":68,"indexYears":69,"academicFieldIds":413,"indexDatabaseRanking":72},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":409,"label":410,"description":411,"key":65,"publicationTags":412,"standard":18},[],{"EN":62,"VI":62},{"EN":62,"VI":64},[67],[71],{"id":74,"indexDatabase":415,"url":89,"indexYears":18,"academicFieldIds":420,"indexDatabaseRanking":18},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":416,"label":417,"description":418,"key":85,"publicationTags":419,"standard":18},[],{"EN":81,"VI":81},{"VI":83,"EN":84},[87,88],[91],{"impactFactor":19,"impactFactorByYear":422,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":423,"totalCitation":19,"totalCitationByYear":424,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":425,"hindexLast5Year":19,"hindex":19},{},{"1992":94},{},{},{"volume":427,"pages":429},{"VOID":428},"30",{"VOID":430},"417-435","2007-09-01",2007,{"id":434,"createTime":435,"updateTime":436,"relativeEntities":437,"slug":438,"properties":439,"entityType":115,"verifyStatus":350,"verifyTime":436,"verifyNote":351,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":446,"fullTextUrl":18,"authors":447,"publicationType":134,"publisherRelationship":478,"citationCount":18,"citationInfo":18,"publishDate":511,"publishYear":512,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":170},"a6a30c57-9298-480f-b383-05b7f2d00b08","2023-12-12T17:06:40.574+00:00","2025-02-23T23:50:04.802+00:00",[],"Obtaining-Informed-Consent-for-Research-With-Psychiatric-Patients-The-Controversy-Continues",{"references":440,"title":442,"doi":444},{"VOID":441},"1973\nAnnas, 1977\nAppelbaum, 1982, Competency to consent to research: A psychiatric overview, Arch. Gen. Psychiatry, 29, 951, 10.1001\u002Farchpsyc.1982.04290080061009\nAppelbaum, P. S., and Roth, L. H.: The structure of informed consent in psychiatric research. Behav. Sci. Law, in press\nAppelbaum, 1982, The therapeutic misconception: Informed consent in psychiatric research, Int. J. Law Psychiatry, 5, 319, 10.1016\u002F0160-2527(82)90026-7\nBigelow, L. B.: Research Using as Subjects Institutionalized Chronic Schizophrenic Patients: Issues Surrounding Consent and Refusal. Talk presented at the Conference on Public Responsibility in Medicine and Research, Asilomar, California, May 9, 1983\nBrady, 1982, The evolution of regulatory influences on research with human subjects\nCardon, 1976, Injuries to research subjects. A survey of investigators, N. Engl. J. Med., 295, 650, 10.1056\u002FNEJM197609162951205\nCarroll, 1980, Research as an impetus to improved treatment, Arch. Gen. Psychiatry, 37, 377, 10.1001\u002Farchpsyc.1980.01780170019001\nChalkley, 1977, Federal constraints: Earned on unearned?, Am. J. Psychiatry, 134, 911, 10.1176\u002Fajp.134.8.911\nCooke, R. A., and Tannenbaum, A. S.: A survey of institutional review boards and research involving human subjects. In Appendix to Report and Recommendations, Institutional Review Boards. Washington, D.C., The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. DHEW Publication No. (OS) 78-0009, November 1, 1977\nCourt holds Maryland prison vaccine testing program constitutional. IRB, 1:10, October 1979\n1981, Final regulations amending basic HHS policy for the protection of human research subjects, Federal Register, 46, 8366\n1979, Belmont Report: Ethical principles and guidelines for the protection of human subjects of research, Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, Federal Register, 44, 23192\n1978, Protection of human subjects. Proposed regulations on research involving those institutionalized as mentally disabled, Federal Register, 43, 53950\n1978, Protection of human subjects. Research involving those institutionalized as mentally infirm: Report and recommendations for public comment, Federal Register, 43, 11328\nEisenberg, 1977, The social imperatives of medical research. Impeding medical research, no less than performing it, has ethical consequences. Not to act is to act, Science, 198, 1105, 10.1126\u002Fscience.337491\nFletcher, 1973, Realities of patient consent to medical research, Hastings Center Studies, 1, 39, 10.2307\u002F3527472\nFrenkel, 1977, Human experimentation: Codes of ethics, Leg. Med. Q., 1, 7\nGoldiamond, 1976, Protection of human subjects and patients: A social contingency analysis of distinctions between research and practice, and its implications, Behaviorism, 4, 1\nGray, 1978, Complexities of informed consent, Am. Acad. Pol. Soc. Sci., 437, 37, 10.1177\u002F000271627843700104\nGray, 1978, Research involving human subjects. The performance of institutional review boards is assessed in this empirical study, Science, 201, 1094, 10.1126\u002Fscience.356268\nGreenwald, 1982\nGruenberg, 1967, The social breakdown syndrome—Some origins, Am. J. Psychiatry, 123, 1481, 10.1176\u002Fajp.123.12.1481\nGrundner, 1981, How to make consent forms more readable, IRB, 3, 9, 10.2307\u002F3563861\nHeath, 1979, The IRB’s monitoring function: Four concepts of monitoring, IRB, 1, 1, 10.2307\u002F3564385\nIllinois lawsuits resolved by guidelines on research with mentally ill. IRB, 1:8, October 1979\nKaimowitz v. Department of Mental Health for the State of Michigan. No. 73–19434–AW (Mich. Cir. Ct., Wayne County, July 10, 1973). Mental Disability Law Reporter, 1:147, 1976\nKalman, 1982, A controlled study of satisfaction among psychobiology research patients, Am. J. Psychiatry, 139, 344, 10.1176\u002Fajp.139.3.344\nKetai, 1981, Family influence in the recruitment of schizophrenic research subjects, Am. J. Psychiatry, 138, 351, 10.1176\u002Fajp.138.3.351\nKocsis, 1981, The effect of psychobiological research on treatment outcome. A controlled study, Arch. Gen. Psychiatry, 33, 511, 10.1001\u002Farchpsyc.1980.01780300023002\nLevine, 1981\nLidz, 1983\nLidz, 1983, The signed form—Informed consent?\nLipsett, 1982, On the nature and ethics of phase 1 clinical trials of cancer chemotherapies, J.A.M.A., 248, 941, 10.1001\u002Fjama.1982.03330080023022\nLubasch, A. H.: Court is told to hold a trial in the death of drug test subject. New York Times, September 14, 1982, p. 7, col. 1\nMacklin, 1981, “Due” and “undue” inducements: On paying money to research subjects, IRB, 3, 1, 10.2307\u002F3564136\nMcCabe, 1977, Human rights and interviews, Arch. Gen. Psychiatry, 34, 1369, 10.1001\u002Farchpsyc.1977.01770230111011\nMcCrae, 1982, Are stress questionnaires stressful?, IRB, 4, 1, 10.2307\u002F3564375\nMeisel, 1983, Toward an informed discussion of informed consent: A review of the empirical studies, Ariz. Law Rev., 25, 265\nMeisel, 1977, Toward a model of the legal doctrine of informed consent, Am. J. Psychiatry, 134, 285, 10.1176\u002Fajp.134.3.285\nMurphy, 1975, Total institutions and the possibility of consent to organic therapies, Human Rights, 5, 25\nOstfeld, 1980, Older research subjects: Not homogeneous, not especially vulnerable, IRB, 2, 7, 10.2307\u002F3563997\nPark, 1967, Effects of informed consent on research patients and study results, J. Nerv Ment. Dis., 145, 349, 10.1097\u002F00005053-196711000-00001\nPresident’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research: Compensating for Research Injuries. The Ethical and Legal Implications of Programs to Redress Injured Subjects. Volume One: Report. Govt. Print. Off. (No. 040-000-00455-6). Washington, D.C., Supt. of Docs., June 1982\nPresident’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research: Protecting Human Subjects. The Adequacy and Uniformity of Federal Rules and Their Implementation. Govt. Print. Off. (No. 040-000-00452-1). Washington, D.C., Supt. of Docs., December 1981, p. 73\nPresident’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research: Second Biennial Report on the Implementing Human Research Regulation. The Adequacy and Uniformity of Federal Rules and of their Implementation. Washington, D.C., Govt. Print. Off, 1983\nPrisoner loses suit claiming coercion to participate in research. IRB, 1:8, August\u002FSeptember 1979\nPryce, 1978, Clinical research upon mentally ill subjects who cannot give informed consent, B. J. Psychiatry, 133, 366, 10.1192\u002Fbjp.133.4.366\nPublic response critical of HEW regulations on mentally disabled. IRB, 1:8, April 1979\n1970, Legal therapy for the doctor-patient relationship, Yale Law J., 79, 1533, 10.2307\u002F795271\nRiecken, 1982, Informed consent to biomedical research in Veterans Administration hospitals, J.A.M.A., 248, 344, 10.1001\u002Fjama.1982.03330030050025\nRobbins, W.: Dioxin tests conducted on 70 Philadelphia inmates, now unknown, in 60 s. New York Times, July 17, 1983, p. 10, col. 1\nRobertson, 1982, Taking consent seriously: IRB intervention in the consent process, IRB, 4, 1, 10.2307\u002F3564226\nRoth, 1982, Competency to decide about treatment or research. An overview of some empirical data, Int. J. Law Psychiatry, 5, 29, 10.1016\u002F0160-2527(82)90013-9\nRothman, 1982, A new look at Tuskegee and Willowbrook, The Hastings Center Report, 12, 5, 10.2307\u002F3561798\nSacks, 1974, Recovery from delusions. Three phases documented by patient’s interpretation of research procedures, Arch. Gen. Psychiatry, 30, 117, 10.1001\u002Farchpsyc.1974.01760070093015\nShah, S. A.: Personal communication, 1980\nSiris, 1979, Intrapsychic structural effects of psychiatric research, Am. J. Psychiatry, 136, 1567, 10.1176\u002Fajp.136.12.1567\nStanley, 1981, Preliminary findings on psychiatric patients as research participants: A population at risk?, Am. J. Psychiatry, 138, 669, 10.1176\u002Fajp.138.5.669\n1978, A statement of principles of ethical conduct for neuropsychopharmacologic research in human subjects\nX-rays beamed on prisoners to test sterility by radiation. New York Times, February 29, 1976, p. 37, col. 1",{"EN":443},"Obtaining Informed Consent for Research With Psychiatric Patients: The Controversy Continues",{"VOID":445},"10.1016\u002Fs0193-953x(18)30794-9","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0193953X18307949",[448,463],{"id":449,"sortIndex":94,"researcher":18,"roles":450,"affiliations":451,"properties":460},"ec60dd16-1a46-4e69-ab11-5425c6b96fba",[122],[452],{"id":18,"sortIndex":19,"affiliation":453,"properties":18},{"id":454,"createTime":455,"updateTime":455,"relativeEntities":456,"slug":18,"properties":457,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"c408ed8d-10ae-4d44-9194-5c93ec1bd266","2023-12-12T17:06:27.242+00:00",[],{"title":458},{"VI":459},"Assistant Professor of Psychiatry and Adjunct Associate Professor of Law, University of Pittsburgh Schools of Medicine and Law; Co-director, Law and Psychiatry Program, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania",{"title":461},{"VI":462},"Paul S. Appelbaum",{"id":464,"sortIndex":19,"researcher":18,"roles":465,"affiliations":466,"properties":475},"a11c0d79-6528-4d3b-a540-1fb618274033",[122],[467],{"id":18,"sortIndex":19,"affiliation":468,"properties":18},{"id":469,"createTime":470,"updateTime":470,"relativeEntities":471,"slug":18,"properties":472,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"c5558fee-53ed-41d9-8ce6-57325b02d0c7","2023-12-12T17:06:40.593+00:00",[],{"title":473},{"VI":474},"Professor of Psychiatry, University of Pittsburgh School of Medicine; Co-director, Law and Psychiatry Program, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania",{"title":476},{"VI":477},"Loren H. Roth",{"url":446,"publisher":479,"properties":506},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":480,"slug":10,"properties":481,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":484,"manageAffiliations":485,"indexDatabases":486,"url":18,"thumbnailPath":18,"statistic":501,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":482,"title":483},{"VOID":13},{"EN":15},[],[],[487,494],{"id":55,"indexDatabase":488,"url":68,"indexYears":69,"academicFieldIds":493,"indexDatabaseRanking":72},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":489,"label":490,"description":491,"key":65,"publicationTags":492,"standard":18},[],{"EN":62,"VI":62},{"EN":62,"VI":64},[67],[71],{"id":74,"indexDatabase":495,"url":89,"indexYears":18,"academicFieldIds":500,"indexDatabaseRanking":18},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":496,"label":497,"description":498,"key":85,"publicationTags":499,"standard":18},[],{"EN":81,"VI":81},{"VI":83,"EN":84},[87,88],[91],{"impactFactor":19,"impactFactorByYear":502,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":503,"totalCitation":19,"totalCitationByYear":504,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":505,"hindexLast5Year":19,"hindex":19},{},{"1992":94},{},{},{"volume":507,"pages":509},{"VOID":508},"6",{"VOID":510},"551-565","1983-12-01",1983,{"id":514,"createTime":515,"updateTime":516,"relativeEntities":517,"slug":518,"properties":519,"entityType":115,"verifyStatus":17,"verifyTime":516,"verifyNote":116,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":526,"fullTextUrl":18,"authors":527,"publicationType":134,"publisherRelationship":542,"citationCount":18,"citationInfo":18,"publishDate":575,"publishYear":576,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":170},"138beb5f-e27c-427a-99ba-7627a6864f24","2024-01-13T23:26:24.450+00:00","2025-01-11T23:43:16.018+00:00",[],"PSYCHIATRY-AND-PHYSICIAN-ASSISTED-SUICIDE",{"references":520,"title":522,"doi":524},{"VOID":521},"Alpers, 1995, Physician-assisted suicide in Oregon, JAMA, 274, 483, 10.1001\u002Fjama.1995.03530060057034\nAmerican Psychiatric Association, 1994\nAppelbaum, 1992, Psychiatrists and access to abortion, Hospital and Community Psychiatry, 43, 967\nAppelbaum, 1988, Assessing patients' capacities to consent to treatment, N Engl J Med, 319, 1635, 10.1056\u002FNEJM198812223192504\nAppelbaum, 1995, Comparison of standards for assessing patients' capacities to make treatment decisions, Am J Psychiatry, 152, 1033, 10.1176\u002Fajp.152.7.1033\nBaile, 1993, The request for assistance in dying: The need for psychiatric consultation, Gen Hosp Psychiatry, 15, 166\nBarraclough, 1974, A hundred cases of suicide: Clinical aspects, Br J Psychiatry, 125, 355, 10.1192\u002Fbjp.125.4.355\nBattin, 1991, Euthanasia: The way we do it, the way they do it, J Pain Symptom Manage, 6, 298, 10.1016\u002F0885-3924(91)90053-7\nBillings, 1994, Correspondence to “Regulating physician-assisted death.”, N Engl J Med, 331, 1657\nBlock, 1995, Patient requests for euthanasia and assisted suicide in terminal illness: The role of the psychiatrist, Psychosomatics, 36, 445, 10.1016\u002FS0033-3182(95)71625-5\nBreitbart, 1994, Psychiatric aspects of palliative care, 609\nBreitbart, 1994, Psychological and psychiatric interventions in pain control, 245\nBrody, 1992, Assisted death—a compassionate response to a medical failure, N Engl J Med, 327, 1384, 10.1056\u002FNEJM199211053271912\nBrown, 1986, Is it normal for terminally ill patients to desire death, Am J Psychiatry, 143, 208, 10.1176\u002Fajp.143.2.208\nBukberg, 1984, Depression in hospitalized cancer patients, Psychosom Med, 46, 199, 10.1097\u002F00006842-198405000-00002\nBurns, 1994, Dextroamphetamine treatment for depression in terminally ill patients, Psychosomatics, 35, 80, 10.1016\u002FS0033-3182(94)71811-9\nBursztajn, 1986, Depression, self-love, time, and the “right” to suicide, Gen Hosp Psychiatry, 8, 91, 10.1016\u002F0163-8343(86)90091-5\nBursztajn, 1991, Beyond cognition: The role of disordered affective states in impairing competence to consent to treatment, Bull Am Acad Psychiatry Law, 19, 383\nChochinov, 1994, Prevalence of depression in the terminally ill: Effects of diagnostic criteria and symptom threshold judgments, Am J Psychiatry, 151, 537, 10.1176\u002Fajp.151.4.537\nChochinov, 1995, Desire for death in the terminally ill, Am J Psychiatry, 152, 1185, 10.1176\u002Fajp.152.8.1185\nCohen, 1994, Attitudes toward assisted suicide and euthanasia among physicians in Washington state, N Engl J Med, 331, 89, 10.1056\u002FNEJM199407143310206\nConwell, 1991, Rational suicide and the right to die: Reality and myth, N Engl J Med, 325, 1100, 10.1056\u002FNEJM199110103251511\nDiMaggio, 1993, Educating psychiatry residents about death and dying: A national survey, Gen Hosp Psychiatry, 15, 166, 10.1016\u002F0163-8343(93)90120-D\nDorpat, 1960, A study of suicide in the Seattle area, Compr Psychiatry, 1, 349, 10.1016\u002FS0010-440X(60)80058-2\nDrane, 1984, Competency to give an informed consent: A model for making clinical assessments, JAMA, 252, 925, 10.1001\u002Fjama.1984.03350070043021\nDubovsky, 1986, Using electroconvulsive therapy for patients with neurological disease, Hospital and Community Psychiatry, 37, 819\nFoley, 1985, The treatment of cancer pain, N Engl J Med, 313, 845, 10.1056\u002FNEJM198507113130205\nGallup Organization Poll, 1950, Storrs, CN, Roper Center for Public Opinion Research\nGanzini, 1994, The effect of depression treatment on elderly patients' preferences for life-sustaining therapy, Am J Psychiatry, 151, 1631, 10.1176\u002Fajp.151.11.1631\nGianelli, 1995, Assisted suicide showdown headed to high court?, American Medical News, 38, 1\nGralnick, 1993, Suicide in the psychiatric hospital, Child Psychiatry Hum Dev, 24, 3, 10.1007\u002FBF02353713\nGreenhouse, 1995, A17\nHendin, 1995, Assisted suicide, euthanasia, and suicide prevention: The implications of the Dutch experience, Suicide Life Threat Behav, 25, 193\nHendin, 1994, A39\nHendin, 1994, Seduced by death: Doctors, patients, and the Dutch cure, Issues Law Med, 10, 1\nHendin, 1993, Physician-assisted suicide: The dangers of legalization, Am J Psychiatry, 150, 143, 10.1176\u002Fajp.150.1.143\nHowell, 1995, The attitudes of geriatric psychiatrists on physician-assisted suicide, Am Journal of Geriatric Psychiatry, 3, 264\nHuyse, 1993, Euthanasia policy in the Netherlands: The role of consultation-liaison psychiatrists, Hosp Comm Psychiatry, 44, 733\nJonsen, 1993, Living with euthanasia: A futuristic scenario, J Med Philos, 18, 241, 10.1093\u002Fjmp\u002F18.3.241\nKass, 1989, Neither for love nor money: Why doctors must not kill, The Public Interest, 94, 40\nKoenig, 1988, Detection and treatment of depression in older medically ill hospitalized patients, Int J Psychiatry Med, 18, 17, 10.2190\u002FQUP8-XL19-TKXK-CRE5\nLee v Oregon, 891, F. Supp. 1429, 94-6467-HO, 1995 WL 471792 (D. Or. 1995)\nLee, 1992, Depression in the elderly: Effect on patient attitudes toward life-sustaining therapy, J Am Geriatr Soc, 40, 983, 10.1111\u002Fj.1532-5415.1992.tb04473.x\nLevine, 1978, Mental disorders in cancer patients: A study of 100 psychiatric referrals, Cancer, 42, 1385, 10.1002\u002F1097-0142(197809)42:3\u003C1385::AID-CNCR2820420349>3.0.CO;2-0\nMalcolm, 1990, A6\nMarks, 1973, Undertreatment of medical inpatients with narcotic analgesics, Ann Intern Med, 78, 173, 10.7326\u002F0003-4819-78-2-173\nMassie, 1983, Delirium in terminally ill cancer patients, Am J Psychiatry, 140, 1048, 10.1176\u002Fajp.140.8.1048\nMcCue, 1995, The naturalness of dying, JAMA, 273, 1039, 10.1001\u002Fjama.1995.03520370081041\nMeisel, 1989\nMiller, 1995, Professional integrity and physician-assisted death, Hastings Cent Rep, 25, 8, 10.2307\u002F3562107\nPauker, 1990, Paradoxical patient reactions to psychiatric life support: Clinical and ethical considerations, Am J Psychiatry, 147, 488, 10.1176\u002Fajp.147.4.488\nPreston, 1994, Professional norms and physician attitudes toward euthanasia, Journal of Law, Medicine & Ethics, 22, 36, 10.1111\u002Fj.1748-720X.1994.tb01273.x\nQuill, 1992, Care of the hopelessly ill: Proposed clinical criteria for physician-assisted suicide, N Engl J Med, 327, 1380, 10.1056\u002FNEJM199211053271911\nRich, 1986, San Diego suicide study, Arch Gen Psychiatry, 43, 577, 10.1001\u002Farchpsyc.1986.01800060071009\nRobins, 1959, Some clinical considerations in the prevention of suicide based on a study of 134 successful suicides, Am J Public Health, 49, 888, 10.2105\u002FAJPH.49.7.888\nRodin, 1986, Depression in the medically ill: An overview, Am J Psychiatry, 143, 696, 10.1176\u002Fajp.143.6.696\nSeravalli, 1988, The dying patient, the physician, and the fear of death, N Engl J Med, 319, 1728, 10.1056\u002FNEJM198812293192609\nSullivan, 1994, Depression, competence, and the right to refuse lifesaving medical treatment, Am J Psychiatry, 151, 971, 10.1176\u002Fajp.151.7.971\nvan der Maas, 1991, Euthanasia and other medical decisions concerning the end of life, Lancet, 338, 669, 10.1016\u002F0140-6736(91)91241-L",{"EN":523},"PSYCHIATRY AND PHYSICIAN-ASSISTED SUICIDE",{"VOID":525},"10.1016\u002Fs0193-953x(05)70298-7","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0193953X05702987",[528,535],{"id":529,"sortIndex":94,"researcher":18,"roles":530,"affiliations":531,"properties":532},"4cac15b1-c095-421c-ab96-71b5e394e031",[122],[],{"title":533},{"VI":534},"Mark D. Sullivan",{"id":536,"sortIndex":19,"researcher":18,"roles":537,"affiliations":538,"properties":539},"a137eddf-7b96-4923-bb44-18579cb24638",[122],[],{"title":540},{"VI":541},"Thomas S. Zaubler",{"url":526,"publisher":543,"properties":570},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":544,"slug":10,"properties":545,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":548,"manageAffiliations":549,"indexDatabases":550,"url":18,"thumbnailPath":18,"statistic":565,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":546,"title":547},{"VOID":13},{"EN":15},[],[],[551,558],{"id":55,"indexDatabase":552,"url":68,"indexYears":69,"academicFieldIds":557,"indexDatabaseRanking":72},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":553,"label":554,"description":555,"key":65,"publicationTags":556,"standard":18},[],{"EN":62,"VI":62},{"EN":62,"VI":64},[67],[71],{"id":74,"indexDatabase":559,"url":89,"indexYears":18,"academicFieldIds":564,"indexDatabaseRanking":18},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":560,"label":561,"description":562,"key":85,"publicationTags":563,"standard":18},[],{"EN":81,"VI":81},{"VI":83,"EN":84},[87,88],[91],{"impactFactor":19,"impactFactorByYear":566,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":567,"totalCitation":19,"totalCitationByYear":568,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":569,"hindexLast5Year":19,"hindex":19},{},{"1992":94},{},{},{"volume":571,"pages":573},{"VOID":572},"19",{"VOID":574},"413-427","1996-09-01",1996,{"id":578,"createTime":579,"updateTime":580,"relativeEntities":581,"slug":582,"properties":583,"entityType":115,"verifyStatus":350,"verifyTime":580,"verifyNote":351,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":590,"fullTextUrl":18,"authors":591,"publicationType":134,"publisherRelationship":622,"citationCount":18,"citationInfo":18,"publishDate":655,"publishYear":656,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":170},"658185bf-15df-46b8-a589-762242f973ad","2023-12-31T14:49:27.735+00:00","2025-01-31T23:43:05.477+00:00",[],"Nursing-Care-in-Electroconvulsive-Therapy",{"references":584,"title":586,"doi":588},{"VOID":585},"Abrams, 1988\nAhern, 1981, Electroconvulsive therapy: An effective treatment, AORN J, 24, 463, 10.1016\u002FS0001-2092(07)62274-1\n1982\n1990\nBarker, 1990, Shock story, Nursing Times, 86(8), 52\nBaxter, 1986, Informing patients about electroconvulsive therapy: Effects of a videotape presentation, Convulsive Therapy, 2, 25\nCochran, 1984, A change of mind about ECT, Am J Nurs, 8, 1004\nCoffey, 1990, Electroconvulsive therapy: An update, Hosp Community Psychiatry, 41, 515\nCohen, 1970, The effects of specific emotional support on anxiety levels prior to electroconvulsive therapy, Nurs Res, 19, 163\nCulver, 1980, ECT and problems of informed consent, Am J Psychiatry, 137, 586, 10.1176\u002Fajp.137.5.586\nDevanand, 1988, The development of mania and organic euphoria during ECT, J Clin Psychiatry, 49, 69\nDuffy, 1989, Electroconvulsive therapy: The perioperative process, AORN J, 50, 806, 10.1016\u002FS0001-2092(07)66014-1\nFine, 1985, Electroshock: Exploding the myth, RN, 48, 58\nFink, 1987, Is ECT use decreasing? Convulsive Therapy, 3, 171\nFreeman, 1986, Patients’ experiences and attitudes to electroconvulsive therapy, Ann NY Acad Sci, 462, 341, 10.1111\u002Fj.1749-6632.1986.tb51268.x\nGomez, 1975, Subjective side effects of ECT, Br J Psychiatry, 127, 609, 10.1192\u002Fbjp.127.6.609\nJanicak, 1985, ECT: An assessment of mental health professionals’ knowledge and attitudes, J Clin Psychiatry, 46, 262\nLitwack, 1988, Practical points in the care of the postelectroconvulsive therapy patient, Journal of Post Anesthesia Nursing, 3, 182\nMcClure, 1969, A device for preventing dental injuries during ECT, Hosp Community Psychiatry, 20, 357\nMiller, 1985, Factors affecting amnesia, seizure duration, and efficacy in ECT, Am J Psychiatry, 142, 692, 10.1176\u002Fajp.142.6.692\nMulaik, 1979, Nurses’ questions about electroconvulsive therapy, J Psychosoc Nurs Ment Health Serv, 17, 15, 10.3928\u002F0279-3695-19790201-03\nRose, 1985, Consensus Development Conference Statement. Bethesda, MD, National Institute of Mental Health and National Institutes of Health, JAMA, 254, 2103\nRoth, 1977, Tests of competency to consent for treatment, Am J Psychiatry, 134, 279, 10.1176\u002Fajp.134.3.279\n1987, RCN nursing guidelines for ECT, Convulsive Therapy, 3, 158\nSands, 1987, Understanding ECT, J Psychosoc Nurs Ment Health Serv, 25, 27, 10.3928\u002F0279-3695-19870801-14\nSchneider, 1981, The recovery room as special procedures unit, AORN J, 34, 490, 10.1016\u002FS0001-2092(07)62276-5\nSquires, 1977, ECT and memory loss, Am J Psychiatry, 134, 997, 10.1176\u002Fajp.134.9.997\nStuart, 1991, Somatic therapies and psychiatric nursing, 688\nSuedfeld, 1989, Reduction of post-ECT memory complaints through brief, partial restricted environmental stimulation (REST), Prog Neuropsychopharmacol Biol Psychiatry, 13, 693, 10.1016\u002F0278-5846(89)90057-2\nSwartz, 1989, Comparison of atropine with glycopyrrolate for use in ECT, Convulsive Therapy, 5, 56\nTalbot, 1986, ECT: Exploring myths, examining attitudes, J Psychosoc Nurs Ment Health Serv, 24, 6, 10.3928\u002F0279-3695-19860301-05\nTaylor, 1983, Consent, competency and ECT: A psychiatrist’s view, J Med Ethics, 9, 146, 10.1136\u002Fjme.9.3.146",{"EN":587},"Nursing Care in Electroconvulsive Therapy",{"VOID":589},"10.1016\u002Fs0193-953x(18)30280-6","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0193953X18302806",[592,607],{"id":593,"sortIndex":94,"researcher":18,"roles":594,"affiliations":595,"properties":604},"6db74ff3-8d16-4e67-a555-b2eef2d96691",[122],[596],{"id":18,"sortIndex":19,"affiliation":597,"properties":18},{"id":598,"createTime":599,"updateTime":599,"relativeEntities":600,"slug":18,"properties":601,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"0d701cb9-b3c9-49be-817c-09b309874289","2023-12-31T14:49:27.843+00:00",[],{"title":602},{"VI":603},"Professor of Nursing, Associate Professor of Psychiatry, and Chief of the Division of Psychiatric Nursing, Medical University of South Carolina, Charleston, South Carolina",{"title":605},{"VI":606},"Gail W. Stuart",{"id":608,"sortIndex":19,"researcher":18,"roles":609,"affiliations":610,"properties":619},"4f89b784-016b-4123-89a3-12deb8acb4c6",[122],[611],{"id":18,"sortIndex":19,"affiliation":612,"properties":18},{"id":613,"createTime":614,"updateTime":614,"relativeEntities":615,"slug":18,"properties":616,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"4da1bdd4-97fc-4baa-b70d-b4fc6d234137","2023-12-31T14:49:27.774+00:00",[],{"title":617},{"VI":618},"Program Nurse Specialist, Institute of Psychiatry, Medical University of South Carolina, Charleston, South Carolina",{"title":620},{"VI":621},"Carol M. Burns",{"url":590,"publisher":623,"properties":650},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":624,"slug":10,"properties":625,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":628,"manageAffiliations":629,"indexDatabases":630,"url":18,"thumbnailPath":18,"statistic":645,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":626,"title":627},{"VOID":13},{"EN":15},[],[],[631,638],{"id":55,"indexDatabase":632,"url":68,"indexYears":69,"academicFieldIds":637,"indexDatabaseRanking":72},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":633,"label":634,"description":635,"key":65,"publicationTags":636,"standard":18},[],{"EN":62,"VI":62},{"EN":62,"VI":64},[67],[71],{"id":74,"indexDatabase":639,"url":89,"indexYears":18,"academicFieldIds":644,"indexDatabaseRanking":18},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":640,"label":641,"description":642,"key":85,"publicationTags":643,"standard":18},[],{"EN":81,"VI":81},{"VI":83,"EN":84},[87,88],[91],{"impactFactor":19,"impactFactorByYear":646,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":647,"totalCitation":19,"totalCitationByYear":648,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":649,"hindexLast5Year":19,"hindex":19},{},{"1992":94},{},{},{"volume":651,"pages":653},{"VOID":652},"14",{"VOID":654},"971-984","1991-12-01",1991,{"id":658,"createTime":659,"updateTime":659,"relativeEntities":660,"slug":18,"properties":661,"entityType":115,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":668,"fullTextUrl":18,"authors":669,"publicationType":134,"publisherRelationship":728,"citationCount":18,"citationInfo":18,"publishDate":761,"publishYear":762,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":170},"dc51ef09-936c-4933-b8c3-da5436a8e671","2023-12-26T23:42:58.051+00:00",[],{"references":662,"title":664,"doi":666},{"VOID":663},"1994\nAndrews, 1986, Monosymptomatic hypochondriacal psychosis manifesting as delusions of infestation: Case studies of treatment with haloperidol, J Clin Psychiatry, 47, 188\nAyd, 1978, Haloperidol: Twenty years’ clinical experience, J Clin Psychiatry, 39, 807\nBerner, 1984, Course and outcome of delusional psychoses, Psychopathology, 17, 28, 10.1159\u002F000284000\nBerrios, 1985, Delusional parasitosis and physical disease, Compr Psychiatry, 26, 395, 10.1016\u002F0010-440X(85)90077-X\nBishop, 1980, An olfactory reference syndrome—Monosymptomatic hypochondriasis, J Clin Psychiatry, 41, 57\nBishop, 1980, Monosymptomatic hypochondriasis, Psychosomatics, 21, 731, 10.1016\u002FS0033-3182(80)73618-6\nBleuler, 1924\nBleuler, 1950\nBotschev, 1991, Opiate receptor antagonists for delusional parasitosis [letter], Biol Psychiatry, 30, 530, 10.1016\u002F0006-3223(91)90322-D\nDamiani, 1990, Pimozide in delusions of parasitosis, J Am Acad Dermatol, 22, 312, 10.1016\u002FS0190-9622(08)80767-0\nEllinwood, 1969, Amphetamine psychosis: A multidimensional process, Sem Psychiatry, 1, 208\nFrances, 1989, Treating a woman who believes she has bugs under her skin, Hosp Community Psychiatry, 40, 1113\nFrithz, 1979, Delusions of infestation: Treatment by depot injections of neuroleptics, Clin Exp Dermatol, 4, 485, 10.1111\u002Fj.1365-2230.1979.tb01645.x\nGerdes T, Baker P: Folie a famille: A shared delusion of parasitosis in four generations, in press\nGould, 1976, Delusions of parasitosis: An approach to the problem, Arch Dermatol, 112, 1745, 10.1001\u002Farchderm.1976.01630370033007\nGriffith, 1966, A study of illicit amphetamine drug traffic in Oklahoma City, Am J Psychiatry, 127, 560, 10.1176\u002Fajp.123.5.560\nHamann, 1982, Delusions of infestation treated by pimozide: A double-blind crossover clinical study, Acta Dermatovener, 62, 55\nHopkinson, 1970, Delusions of infestation, Acta Psychiatr Scand, 46, 111, 10.1111\u002Fj.1600-0447.1970.tb02106.x\nHopkinson, 1973, The psychiatric syndrome of infestation, Psychiatrica Clinica, 6, 330\nHunt, 1987, Delusional parasitosis [letter], Br J Psychiatry, 150, 713, 10.1192\u002Fbjp.150.5.713b\nIwu, 1989, Delusional halitosis: Review of the literature and analysis of 32 cases, Br Dent J, 167, 294\nJohnson, 1985, Delusions of parasitosis: Differential diagnosis and treatment, South Med J, 78, 914, 10.1097\u002F00007611-198508000-00005\nJohnson, 1983, Pimozide in delusions of parasitosis [letter], J Clin Psychiatry, 44, 233\nKendler, 1980, The nosologic validity of paranoia (simple delusional disorder), Arch General Psychiatry, 37, 699, 10.1001\u002Farchpsyc.1980.01780190097012\nKendler, 1981, Paranoid psychosis (delusional disorder) and schizophrenia, Arch Gen Psychiatry, 38, 547, 10.1001\u002Farchpsyc.1980.01780300059007\n1983, Lancet: The matchbox sign [editorial], Lancet, i, 26\nLiebowitz, 1978, Phenelzine and delusions of parasitosis: A case report, Am J Psychiatry, 135, 1565, 10.1176\u002Fajp.135.12.1565\nLindskov, 1985, Delusions of infestation treated with pimozide: A followup study, Acta Derm Venereol (Stockholm), 65, 267, 10.2340\u002F0001555565267270\nLyell, 1983, Delusions of parasitosis, Br J Dermatol, 108, 485, 10.1111\u002Fj.1365-2133.1983.tb04604.x\nMacaskill, 1987, Delusions of parasitosis: Successful nonpharmacological treatment of folie a deux, Br J Psychiatry, 150, 261, 10.1192\u002Fbjp.150.2.261\nMacNamara, 1928, Cutaneous and visual hallucinations, Lancet, 214, 807, 10.1016\u002FS0140-6736(00)76765-1\nMarneros, 1988, Delusional parasitosis, a comparitive study to late- onset schizophrenia and organic mental disorders due to cerebral arteriosclerosis, Psychopathology, 21, 267, 10.1159\u002F000284569\nMayer-Gross, 1960\nMick, 1987, Delusions of parasitosis: Healing impact of the physician-patient relationship, Psychosomatics, 28, 596, 10.1016\u002FS0033-3182(87)72460-8\nMitchell, 1989, Successful treatment of chronic delusional parasitosis, Br J Psychiatry, 155, 556, 10.1192\u002Fbjp.155.4.556\nMorris, 1991, Delusional infestation, Br J Psychiatry, 159, 83, 10.1192\u002FS0007125000296542\nMorris, 1987, Delusional infestation in late life [letter], Br J Psychiatry, 151, 272, 10.1192\u002Fbjp.151.2.272a\nMorris, 1988, When delusions of infestation afflict the elderly, Geriatr Med, 18, 57\nMunro, 1982, Paranoia revisited, Br J Psychiatry, 141, 344, 10.1192\u002Fbjp.141.4.344\nMunro, 1991, Phenomenological aspects of monodelusional disorders, Br J Psychiatry, 159, 62, 10.1192\u002FS0007125000296505\nMusalek, 1990, The position of delusional parasitosis in psychiatric nosology and classification, Psychopathology, 23, 115, 10.1159\u002F000284647\nMusalek, 1989, Regional brain function in hallucinations: A study of regional cerebral blood flow with 99m-Tc-HMPAO-SPECT in patients with auditory hallucinations, tactile hallucinations, and normal controls, Compr Psychiatry, 30, 99, 10.1016\u002F0010-440X(89)90123-5\nPryse-Phillips, 1971, An olfactory reference syndrome, Acta Psychiatr Scand, 47, 484, 10.1111\u002Fj.1600-0447.1971.tb03705.x\nRefsum, 1983, Paranoiac psychoses: A follow-up, Neuropsychobiology, 10, 75, 10.1159\u002F000117989\nReilly, 1977, Monosymptomatic hypochondriacal psychosis: Presentation and treatment, Proceedings of the Royal Society of Medicine, 70, 39, 10.1177\u002F0035915777070S1008\nReilly, 1988, Delusional infestation, Br J Psychiatry, 153, 44, 10.1192\u002FS0007125000298991\nReilly, 1986, The presentation and treatment of delusional parasitosis: A dermatological perspective, Int Clin Psychopharmacol, 1, 340, 10.1097\u002F00004850-198610000-00009\nReilly, 1978, Successful treatment with pimozide of delusional parasitosis, Br J Dermatol, 98, 457, 10.1111\u002Fj.1365-2133.1978.tb06541.x\nRenvoize, 1987, Delusional infestation and dementia: A case report, Br J Psychiatry, 150, 403, 10.1192\u002Fbjp.150.3.403\nRetterstol, 1968, Paranoid psychoses with hypochondriacal delusions as the main delusion, Acta Psychiatr Scand, 44, 334, 10.1111\u002Fj.1600-0447.1968.tb07641.x\nRiding, 1975, Pimozide in the treatment of monosymptomatic hypochondriacal psychosis, Acta Psychiatr Scand, 52, 23, 10.1111\u002Fj.1600-0447.1975.tb00019.x\nRoberts, 1977, Delusions of parasitosis, BMJ, 1, 1219, 10.1136\u002Fbmj.1.6070.1219-b\nShah, 1988, Delusions of parasitosis, South Med J, 81, 939, 10.1097\u002F00007611-198807000-00037\nSiegel, 1978, Cocaine hallucinations, Am J Psychiatry, 135, 309, 10.1176\u002Fajp.135.3.309\nSpensley, 1972, Psychosis during methylphenidate abuse, N Engl J Med, 286, 880, 10.1056\u002FNEJM197204202861607\nStevens, 1951\nTullett, 1965, Delusions of parasitosis, Br J Dermatol, 77, 448, 10.1111\u002Fj.1365-2133.1965.tb14676.x\nWessely, 1987, Delusional parasitosis, Br J Psychiatry, 151, 560, 10.1192\u002Fbjp.151.4.560b\nWilson, 1946, Delusions of parasitosis, Archives of Dermatology and Syphilology, 54, 39, 10.1001\u002Farchderm.1946.01510360043006\nWinokur, 1977, Delusional disorder (paranoia), Compr Psychiatry, 18, 511, 10.1016\u002FS0010-440X(97)90001-8\nWinokur, 1986, Classification of chronic psychoses including delusional disorders and schizophrenias, Psychopathology, 19, 30, 10.1159\u002F000284426\nWykoff, 1987, Delusions of parasitosis: A review, Reviews of Infectious Diseases, 9, 433, 10.1093\u002Fclinids\u002F9.3.433",{"EN":665},"Delusional Infestation",{"VOID":667},"10.1016\u002Fs0193-953x(18)30059-5","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0193953X18300595",[670,687,709],{"id":671,"sortIndex":19,"researcher":18,"roles":672,"affiliations":673,"properties":684},"3d9b2e54-60cc-4cd7-8c26-500cd52ea7b5",[122],[674],{"id":18,"sortIndex":19,"affiliation":675,"properties":18},{"id":676,"createTime":677,"updateTime":678,"relativeEntities":679,"slug":680,"properties":681,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"043837cf-7693-43d4-b550-f03f51fc300a","2023-12-26T23:42:58.086+00:00","2025-06-11T17:30:09.627+00:00",[],"From-the-Department-of-Psychiatry-The-University-of-Iowa-College-of-Medicine-Iowa-City-Iowa",{"title":682},{"VI":683},"From the Department of Psychiatry, The University of Iowa College of Medicine, Iowa City, Iowa",{"title":685},{"VI":686},"Peggy B. Baker",{"id":688,"sortIndex":94,"researcher":18,"roles":689,"affiliations":690,"properties":706},"33b6993c-6ed3-4d98-a406-d06120de3c8f",[122],[691,701],{"id":692,"sortIndex":94,"affiliation":693,"properties":700},"6469aafa-1390-46fe-b33a-42f88f3864a0",{"id":694,"createTime":695,"updateTime":695,"relativeEntities":696,"slug":18,"properties":697,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"5d88f0b4-4c2a-462d-8290-d8fb08038bbc","2023-12-26T23:42:58.088+00:00",[],{"title":698},{"VI":699},"The Psychiatry Service, Department of Veterans Affairs Medical Center, Iowa City, Iowa",{},{"id":18,"sortIndex":19,"affiliation":702,"properties":18},{"id":676,"createTime":677,"updateTime":678,"relativeEntities":703,"slug":680,"properties":704,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":705},{"VI":683},{"title":707},{"VI":708},"Brian L. Cook",{"id":710,"sortIndex":264,"researcher":18,"roles":711,"affiliations":712,"properties":725},"d3c1f3a9-061e-4477-9808-0216be07ba78",[122],[713,718],{"id":18,"sortIndex":19,"affiliation":714,"properties":18},{"id":676,"createTime":677,"updateTime":678,"relativeEntities":715,"slug":680,"properties":716,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":717},{"VI":683},{"id":719,"sortIndex":94,"affiliation":720,"properties":724},"5fe976a7-e12a-457d-a8d8-8e21e77caef4",{"id":694,"createTime":695,"updateTime":695,"relativeEntities":721,"slug":18,"properties":722,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},[],{"title":723},{"VI":699},{},{"title":726},{"VI":727},"George Winokur",{"url":668,"publisher":729,"properties":756},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":730,"slug":10,"properties":731,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":734,"manageAffiliations":735,"indexDatabases":736,"url":18,"thumbnailPath":18,"statistic":751,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":732,"title":733},{"VOID":13},{"EN":15},[],[],[737,744],{"id":55,"indexDatabase":738,"url":68,"indexYears":69,"academicFieldIds":743,"indexDatabaseRanking":72},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":739,"label":740,"description":741,"key":65,"publicationTags":742,"standard":18},[],{"EN":62,"VI":62},{"EN":62,"VI":64},[67],[71],{"id":74,"indexDatabase":745,"url":89,"indexYears":18,"academicFieldIds":750,"indexDatabaseRanking":18},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":746,"label":747,"description":748,"key":85,"publicationTags":749,"standard":18},[],{"EN":81,"VI":81},{"VI":83,"EN":84},[87,88],[91],{"impactFactor":19,"impactFactorByYear":752,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":753,"totalCitation":19,"totalCitationByYear":754,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":755,"hindexLast5Year":19,"hindex":19},{},{"1992":94},{},{},{"volume":757,"pages":759},{"VOID":758},"18",{"VOID":760},"345-361","1995-06-01",1995,{"id":764,"createTime":765,"updateTime":765,"relativeEntities":766,"slug":767,"properties":768,"entityType":115,"verifyStatus":350,"verifyTime":765,"verifyNote":351,"syncStatus":17,"languages":783,"translateLanguages":18,"viewCount":19,"primaryUrl":785,"fullTextUrl":18,"authors":786,"publicationType":134,"publisherRelationship":829,"citationCount":864,"citationInfo":865,"publishDate":876,"publishYear":877,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":878,"isForceReanalyzing":170},"b843a08c-54cc-44ee-924d-5f6203d652bf","2024-10-10T23:41:12.842+00:00",[],"Cognitive-Behavioral-Therapy-for-Mood-Disorders-Efficacy-Moderators-and-Mediators",{"mag":769,"keywords":771,"pmc":772,"openalex":774,"abstract":776,"title":777,"pm":779,"doi":781},{"VOID":770},"2068831405",{},{"VOID":773},"2933381",{"VOID":775},"W2068831405",{},{"EN":778},"Cognitive Behavioral Therapy for Mood Disorders: Efficacy, Moderators and Mediators",{"VOID":780},"20599132",{"VOID":782},"10.1016\u002Fj.psc.2010.04.005",[784],"EN","https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0193953X1000047X",[787,808],{"id":788,"sortIndex":94,"researcher":18,"roles":789,"affiliations":790,"properties":801},"d359f5e7-cc74-4530-b54e-c3d1a433ce8d",[],[791],{"id":792,"sortIndex":19,"affiliation":793,"properties":18},"ae5b70cf-23e5-420e-b44a-547581dfe0d1",{"id":794,"createTime":795,"updateTime":795,"relativeEntities":796,"slug":797,"properties":798,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a8f3a82e-203a-4d47-90d2-8bf7cb477255","2024-10-10T23:41:12.878+00:00",[],"Department-of-Psychology-Vanderbilt-University-306-Wilson-Hall-Nashville-TN-37240-USA",{"title":799},{"EN":800},"Department of Psychology,Vanderbilt University,306 Wilson Hall,Nashville,TN 37240,USA",{"openalex":802,"orcid":804,"title":806},{"VOID":803},"A5082277627",{"VOID":805},"https:\u002F\u002Forcid.org\u002F0000-0001-5005-3862",{"EN":807},"Steven D. Hollon",{"id":809,"sortIndex":19,"researcher":18,"roles":810,"affiliations":811,"properties":822},"5eaa32e1-41a4-4fab-8ae3-2ae12bf8fc98",[],[812],{"id":813,"sortIndex":19,"affiliation":814,"properties":18},"a2e91440-e166-4070-bba0-72b85538d75e",{"id":815,"createTime":816,"updateTime":816,"relativeEntities":817,"slug":818,"properties":819,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"f0484413-9c92-4c71-b58c-c7cf225acde5","2024-10-10T23:41:12.865+00:00",[],"Faculty-of-Psychology-and-Education-Department-of-Clinical-Psychology-VU-University-Amsterdam-Van-der-Boechorststraat-1-1018-BX-Amsterdam-The-Netherlands-",{"title":820},{"EN":821},"Faculty of Psychology and Education, Department of Clinical Psychology, VU University Amsterdam, Van der Boechorststraat 1, 1018 BX Amsterdam, The Netherlands.",{"openalex":823,"orcid":825,"title":827},{"VOID":824},"A5057596953",{"VOID":826},"https:\u002F\u002Forcid.org\u002F0000-0002-9602-1548",{"EN":828},"Ellen Driessen",{"url":18,"publisher":830,"properties":857},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":831,"slug":10,"properties":832,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":835,"manageAffiliations":836,"indexDatabases":837,"url":18,"thumbnailPath":18,"statistic":852,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":833,"title":834},{"VOID":13},{"EN":15},[],[],[838,845],{"id":55,"indexDatabase":839,"url":68,"indexYears":69,"academicFieldIds":844,"indexDatabaseRanking":72},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":840,"label":841,"description":842,"key":65,"publicationTags":843,"standard":18},[],{"EN":62,"VI":62},{"EN":62,"VI":64},[67],[71],{"id":74,"indexDatabase":846,"url":89,"indexYears":18,"academicFieldIds":851,"indexDatabaseRanking":18},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":847,"label":848,"description":849,"key":85,"publicationTags":850,"standard":18},[],{"EN":81,"VI":81},{"VI":83,"EN":84},[87,88],[91],{"impactFactor":19,"impactFactorByYear":853,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":854,"totalCitation":19,"totalCitationByYear":855,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":856,"hindexLast5Year":19,"hindex":19},{},{"1992":94},{},{},{"volume":858,"pages":860,"issue":862},{"VOID":859},"33",{"VOID":861},"537-555",{"VOID":863},"3",271,{"total":864,"publishYear":18,"statisticByYear":866},{"2012":867,"2013":868,"2014":868,"2015":869,"2016":870,"2017":871,"2018":872,"2019":868,"2020":873,"2021":874,"2022":869,"2023":875,"2024":51},11,20,23,26,15,16,17,34,24,"2010-09-01",2010,[879,883,887,890,894,897,900,903,906,909,913,917,921,925,929,933,937,941,945,948,952,956,960,964,968,972,976,980,984,988,992,996,1000,1004,1008,1012,1016,1020,1024,1028,1032,1036,1040,1044,1048,1052,1056,1060,1064,1068,1072,1076,1080,1084,1088,1092,1096,1100,1104,1108,1112,1116,1120,1124,1128,1132,1136,1140,1144,1148,1152,1156,1160,1164,1168,1172,1176,1180,1184,1188,1192,1196,1200,1204,1208,1212,1216,1220,1224,1228,1232,1236,1240,1244,1248],{"id":18,"text":880,"url":18,"identifiers":881},"Murray, 1997, Global mortality, disability, and the contribution of risk factors: global burden of disease study, Lancet, 349, 1436, 10.1016\u002FS0140-6736(96)07495-8",{"doi":882},"10.1016\u002FS0140-6736(96)07495-8",{"id":18,"text":884,"url":18,"identifiers":885},"Kessler, 2003, The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R), JAMA, 289, 3095, 10.1001\u002Fjama.289.23.3095",{"doi":886},"10.1001\u002Fjama.289.23.3095",{"id":18,"text":888,"url":18,"identifiers":889},"Keller, 2001, Long-term treatment of recurrent and chronic depression, J Clin Psychiatry, 62, 3",{},{"id":18,"text":891,"url":18,"identifiers":892},"Rush, 2004, Sequenced treatment alternatives to relieve depression (STAR∗D): rationale and design, Control Clin Trials, 25, 119, 10.1016\u002FS0197-2456(03)00112-0",{"doi":893},"10.1016\u002FS0197-2456(03)00112-0",{"id":18,"text":895,"url":18,"identifiers":896},"DeRubeis, 1998, Affective disorders, vol. 6, 339",{},{"id":18,"text":898,"url":18,"identifiers":899},"American Psychiatric Association, 2000",{},{"id":18,"text":901,"url":18,"identifiers":902},"Beck, 1979",{},{"id":18,"text":904,"url":18,"identifiers":905},"Cuijpers P, van Straten A, Driessen E, et al. Depression and dysthymic disorders. In: Hersen M, Sturmey P, editors. Handbook of evidence-based practice in clinical psychology, vol. II. Adult disorders. Hoboken (NJ): Wiley; in press.",{},{"id":18,"text":907,"url":18,"identifiers":908},"Cuijpers, 2001, Are individual and group treatments equally effective in the treatment of depression in adults? A meta-analysis, Eur J Psychiatry, 22, 38",{},{"id":18,"text":910,"url":18,"identifiers":911},"Gloaguen, 1998, A meta-analysis of the effects of cognitive therapy in depressed patients, J Affect Disord, 49, 59, 10.1016\u002FS0165-0327(97)00199-7",{"doi":912},"10.1016\u002FS0165-0327(97)00199-7",{"id":18,"text":914,"url":18,"identifiers":915},"Wampold, 2002, A meta-(re)analysis of the effects of cognitive therapy versus ‘other therapies’ for depression, J Affect Disord, 68, 159, 10.1016\u002FS0165-0327(00)00287-1",{"doi":916},"10.1016\u002FS0165-0327(00)00287-1",{"id":18,"text":918,"url":18,"identifiers":919},"Butler, 2006, The empirical status of cognitive-behavioral therapy: a review of meta-analyses, Clin Psychol Rev, 26, 17, 10.1016\u002Fj.cpr.2005.07.003",{"doi":920},"10.1016\u002Fj.cpr.2005.07.003",{"id":18,"text":922,"url":18,"identifiers":923},"Rush, 1977, Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients, Cognit Ther Res, 1, 17, 10.1007\u002FBF01173502",{"doi":924},"10.1007\u002FBF01173502",{"id":18,"text":926,"url":18,"identifiers":927},"Blackburn, 1981, The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination, Br J Psychiatry, 139, 181, 10.1192\u002Fbjp.139.3.181",{"doi":928},"10.1192\u002Fbjp.139.3.181",{"id":18,"text":930,"url":18,"identifiers":931},"Murphy, 1984, Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression, Arch Gen Psychiatry, 41, 33, 10.1001\u002Farchpsyc.1984.01790120037006",{"doi":932},"10.1001\u002Farchpsyc.1984.01790120037006",{"id":18,"text":934,"url":18,"identifiers":935},"Hollon, 1992, Cognitive therapy and pharmacotherapy for depression: singly and in combination, Arch Gen Psychiatry, 49, 774, 10.1001\u002Farchpsyc.1992.01820100018004",{"doi":936},"10.1001\u002Farchpsyc.1992.01820100018004",{"id":18,"text":938,"url":18,"identifiers":939},"Elkin, 1989, Treatment of depression collaborative research program: general effectiveness of treatments, Arch Gen Psychiatry, 46, 971, 10.1001\u002Farchpsyc.1989.01810110013002",{"doi":940},"10.1001\u002Farchpsyc.1989.01810110013002",{"id":18,"text":942,"url":18,"identifiers":943},"Elkin, 1995, Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program, J Consult Clin Psychol, 63, 841, 10.1037\u002F0022-006X.63.5.841",{"doi":944},"10.1037\u002F0022-006X.63.5.841",{"id":18,"text":946,"url":18,"identifiers":947},"American Psychiatric Association, 2000, Practice guideline for the treatment of patients with major depressive disorder [revision], Am J Psychiatry, 157, 1",{},{"id":18,"text":949,"url":18,"identifiers":950},"Jacobson, 1996, Cognitive behavior therapy vs. pharmacotherapy: now that the jury's returned its verdict, its time to present the rest of the evidence, J Consult Clin Psychol, 64, 74, 10.1037\u002F0022-006X.64.1.74",{"doi":951},"10.1037\u002F0022-006X.64.1.74",{"id":18,"text":953,"url":18,"identifiers":954},"Jacobson, 1996, Prospects for future comparisons between drugs and psychotherapy: lessons from the CBT vs. pharmacotherapy exchange, J Consult Clin Psychol, 64, 104, 10.1037\u002F0022-006X.64.1.104",{"doi":955},"10.1037\u002F0022-006X.64.1.104",{"id":18,"text":957,"url":18,"identifiers":958},"Jarrett, 1999, Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial, Arch Gen Psychiatry, 56, 431, 10.1001\u002Farchpsyc.56.5.431",{"doi":959},"10.1001\u002Farchpsyc.56.5.431",{"id":18,"text":961,"url":18,"identifiers":962},"DeRubeis, 2005, Cognitive therapy vs medications in the treatment of moderate to severe depression, Arch Gen Psychiatry, 62, 409, 10.1001\u002Farchpsyc.62.4.409",{"doi":963},"10.1001\u002Farchpsyc.62.4.409",{"id":18,"text":965,"url":18,"identifiers":966},"Fournier, 2008, Antidepressant medications versus cognitive therapy in depressed patients with or without personality disorder, Br J Psychiatry, 192, 124, 10.1192\u002Fbjp.bp.107.037234",{"doi":967},"10.1192\u002Fbjp.bp.107.037234",{"id":18,"text":969,"url":18,"identifiers":970},"Dimidjian, 2006, Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression, J Consult Clin Psychol, 74, 658, 10.1037\u002F0022-006X.74.4.658",{"doi":971},"10.1037\u002F0022-006X.74.4.658",{"id":18,"text":973,"url":18,"identifiers":974},"Coffman, 2007, Extreme non-response in cognitive therapy: can behavioral activation succeed where cognitive therapy fails?, J Consult Clin Psychol, 75, 531, 10.1037\u002F0022-006X.75.4.531",{"doi":975},"10.1037\u002F0022-006X.75.4.531",{"id":18,"text":977,"url":18,"identifiers":978},"Keller, 2000, A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression, N Engl J Med, 342, 1462, 10.1056\u002FNEJM200005183422001",{"doi":979},"10.1056\u002FNEJM200005183422001",{"id":18,"text":981,"url":18,"identifiers":982},"Hollon, 2002, Treatment and prevention of depression, Psychol Sci Publ Interest, 3, 39, 10.1111\u002F1529-1006.00008",{"doi":983},"10.1111\u002F1529-1006.00008",{"id":18,"text":985,"url":18,"identifiers":986},"Frank, 1991, Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence, Arch Gen Psychiatry, 48, 851, 10.1001\u002Farchpsyc.1991.01810330075011",{"doi":987},"10.1001\u002Farchpsyc.1991.01810330075011",{"id":18,"text":989,"url":18,"identifiers":990},"Hollon, 2006, Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety, Annu Rev Psychol, 57, 285, 10.1146\u002Fannurev.psych.57.102904.190044",{"doi":991},"10.1146\u002Fannurev.psych.57.102904.190044",{"id":18,"text":993,"url":18,"identifiers":994},"Vittengl, 2007, Reducing relapse and recurrence in unipolar depression, a comparative meta-analysis of cognitive-behavioral therapy's effects, J Consult Clin Psychol, 75, 475, 10.1037\u002F0022-006X.75.3.475",{"doi":995},"10.1037\u002F0022-006X.75.3.475",{"id":18,"text":997,"url":18,"identifiers":998},"Hollon, 2005, Prevention of relapse following cognitive therapy vs medications in moderate to severe depression, Arch Gen Psychiatry, 62, 417, 10.1001\u002Farchpsyc.62.4.417",{"doi":999},"10.1001\u002Farchpsyc.62.4.417",{"id":18,"text":1001,"url":18,"identifiers":1002},"Dobson, 2008, Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression, J Consult Clin Psychol, 76, 468, 10.1037\u002F0022-006X.76.3.468",{"doi":1003},"10.1037\u002F0022-006X.76.3.468",{"id":18,"text":1005,"url":18,"identifiers":1006},"Klein, 1996, Preventing hung juries about therapy studies, J Consult Clin Psychol, 64, 81, 10.1037\u002F0022-006X.64.1.81",{"doi":1007},"10.1037\u002F0022-006X.64.1.81",{"id":18,"text":1009,"url":18,"identifiers":1010},"Fava, 1998, Prevention of recurrent depression with cognitive behavioral therapy, Arch Gen Psychiatry, 55, 816, 10.1001\u002Farchpsyc.55.9.816",{"doi":1011},"10.1001\u002Farchpsyc.55.9.816",{"id":18,"text":1013,"url":18,"identifiers":1014},"Fava, 2004, Six-year outcome of cognitive behavior therapy for prevention of recurrent depression, Am J Psychiatry, 161, 1872, 10.1176\u002Fappi.ajp.161.10.1872",{"doi":1015},"10.1176\u002Fappi.ajp.161.10.1872",{"id":18,"text":1017,"url":18,"identifiers":1018},"Paykel, 1999, Prevention of relapse in residual depression by cognitive therapy. A controlled trial, Arch Gen Psychiatry, 56, 829, 10.1001\u002Farchpsyc.56.9.829",{"doi":1019},"10.1001\u002Farchpsyc.56.9.829",{"id":18,"text":1021,"url":18,"identifiers":1022},"Paykel, 2005, Duration of relapse prevention after cognitive therapy for residual depression: follow-up of controlled trial, Psychol Med, 35, 59, 10.1017\u002FS003329170400282X",{"doi":1023},"10.1017\u002FS003329170400282X",{"id":18,"text":1025,"url":18,"identifiers":1026},"Bockting, 2005, Preventing relapse\u002Frecurrence in recurrent depression with cognitive therapy: a randomized controlled trial, J Consult Clin Psychol, 73, 647, 10.1037\u002F0022-006X.73.4.647",{"doi":1027},"10.1037\u002F0022-006X.73.4.647",{"id":18,"text":1029,"url":18,"identifiers":1030},"Teasdale, 2000, Prevention of relapse\u002Frecurrence in major depression by mindfulness-based cognitive therapy, J Consult Clin Psychol, 68, 615, 10.1037\u002F0022-006X.68.4.615",{"doi":1031},"10.1037\u002F0022-006X.68.4.615",{"id":18,"text":1033,"url":18,"identifiers":1034},"Ma, 2004, Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects, J Consult Clin Psychol, 72, 31, 10.1037\u002F0022-006X.72.1.31",{"doi":1035},"10.1037\u002F0022-006X.72.1.31",{"id":18,"text":1037,"url":18,"identifiers":1038},"Perlis, 2002, Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder, J Clin Psychopharmacol, 22, 474, 10.1097\u002F00004714-200210000-00006",{"doi":1039},"10.1097\u002F00004714-200210000-00006",{"id":18,"text":1041,"url":18,"identifiers":1042},"Jarrett, 2001, Preventing recurrent depression using cognitive therapy with and without a continuation phase. A randomized clinical trial, Arch Gen Psychiatry, 58, 381, 10.1001\u002Farchpsyc.58.4.381",{"doi":1043},"10.1001\u002Farchpsyc.58.4.381",{"id":18,"text":1045,"url":18,"identifiers":1046},"Jarrett, 2000, Reducing relapse in depressed outpatients with atypical features: a pilot study, Psychother Psychosom, 69, 232, 10.1159\u002F000012401",{"doi":1047},"10.1159\u002F000012401",{"id":18,"text":1049,"url":18,"identifiers":1050},"Klein, 2004, Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression, J Consult Clin Psychol, 72, 681, 10.1037\u002F0022-006X.72.4.681",{"doi":1051},"10.1037\u002F0022-006X.72.4.681",{"id":18,"text":1053,"url":18,"identifiers":1054},"Blackburn, 1986, A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both, J Affect Disord, 10, 67, 10.1016\u002F0165-0327(86)90050-9",{"doi":1055},"10.1016\u002F0165-0327(86)90050-9",{"id":18,"text":1057,"url":18,"identifiers":1058},"Blackburn, 1997, Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in outpatients with recurrent depression, Br J Psychiatry, 171, 328, 10.1192\u002Fbjp.171.4.328",{"doi":1059},"10.1192\u002Fbjp.171.4.328",{"id":18,"text":1061,"url":18,"identifiers":1062},"Kuyken, 2008, Mindfulness-based cognitive therapy to prevent relapse in recurrent depression, J Consult Clin Psychol, 76, 966, 10.1037\u002Fa0013786",{"doi":1063},"10.1037\u002Fa0013786",{"id":18,"text":1065,"url":18,"identifiers":1066},"Miklowitz, 2007, Psychosocial treatments for bipolar disorder: a 1-year randomized trial from the Systematic Treatment Enhancement Program, Arch Gen Psychiatry, 64, 419, 10.1001\u002Farchpsyc.64.4.419",{"doi":1067},"10.1001\u002Farchpsyc.64.4.419",{"id":18,"text":1069,"url":18,"identifiers":1070},"Lam, 2000, Cognitive therapy for bipolar illness – a pilot study of relapse prevention, Cognit Ther Res, 24, 503, 10.1023\u002FA:1005557911051",{"doi":1071},"10.1023\u002FA:1005557911051",{"id":18,"text":1073,"url":18,"identifiers":1074},"Lam, 2003, A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder, Arch Gen Psychiatry, 60, 145, 10.1001\u002Farchpsyc.60.2.145",{"doi":1075},"10.1001\u002Farchpsyc.60.2.145",{"id":18,"text":1077,"url":18,"identifiers":1078},"Lam, 2005, Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years, Am J Psychiatry, 162, 324, 10.1176\u002Fappi.ajp.162.2.324",{"doi":1079},"10.1176\u002Fappi.ajp.162.2.324",{"id":18,"text":1081,"url":18,"identifiers":1082},"Ball, 2006, A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change, J Clin Psychiatry, 67, 277, 10.4088\u002FJCP.v67n0215",{"doi":1083},"10.4088\u002FJCP.v67n0215",{"id":18,"text":1085,"url":18,"identifiers":1086},"Zaretzky, 2008, Is cognitive-behavioural therapy more effective than psychoeducation in bipolar disorder?, Can J Psychiatry, 53, 441, 10.1177\u002F070674370805300709",{"doi":1087},"10.1177\u002F070674370805300709",{"id":18,"text":1089,"url":18,"identifiers":1090},"Scott, 2006, Cognitive-behavioral therapy for severe and recurrent bipolar disorders. Randomised controlled trial, Br J Psychiatry, 188, 313, 10.1192\u002Fbjp.188.4.313",{"doi":1091},"10.1192\u002Fbjp.188.4.313",{"id":18,"text":1093,"url":18,"identifiers":1094},"Lynch, 2010, Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytic review of well-controlled trials, Psychol Med, 40, 9, 10.1017\u002FS003329170900590X",{"doi":1095},"10.1017\u002FS003329170900590X",{"id":18,"text":1097,"url":18,"identifiers":1098},"Lam, 2006, What can we conclude from studies on psychotherapy in bipolar disorder? Invited commentary on: cognitive-behavioral therapy for severe and recurrent bipolar disorders, Br J Psychiatry, 188, 321, 10.1192\u002Fbjp.188.4.321",{"doi":1099},"10.1192\u002Fbjp.188.4.321",{"id":18,"text":1101,"url":18,"identifiers":1102},"Fournier, 2009, Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression, J Consult Clin Psychol, 77, 775, 10.1037\u002Fa0015401",{"doi":1103},"10.1037\u002Fa0015401",{"id":18,"text":1105,"url":18,"identifiers":1106},"Kraemer, 2002, Mediators and moderators of treatment effects in randomized clinical trials, Arch Gen Psychiatry, 59, 877, 10.1001\u002Farchpsyc.59.10.877",{"doi":1107},"10.1001\u002Farchpsyc.59.10.877",{"id":18,"text":1109,"url":18,"identifiers":1110},"Hamilton, 2002, Cognitive therapy of depression: pretreatment patient predictors of outcome, Clin Psychol Rev, 22, 875, 10.1016\u002FS0272-7358(02)00106-X",{"doi":1111},"10.1016\u002FS0272-7358(02)00106-X",{"id":18,"text":1113,"url":18,"identifiers":1114},"Burns, 2000, Does psychotherapy homework lead to improvements in depression in cognitive-behavioral therapy or does improvement lead to increased homework compliance?, J Consult Clin Psychol, 68, 46, 10.1037\u002F0022-006X.68.1.46",{"doi":1115},"10.1037\u002F0022-006X.68.1.46",{"id":18,"text":1117,"url":18,"identifiers":1118},"Jarrett, 1991, Clinical, cognitive, and demographic predictors of response to cognitive therapy for depression: a preliminary report, Psychiatry Res, 37, 245, 10.1016\u002F0165-1781(91)90061-S",{"doi":1119},"10.1016\u002F0165-1781(91)90061-S",{"id":18,"text":1121,"url":18,"identifiers":1122},"Sotksy, 1991, Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program, Am J Psychiatry, 148, 997, 10.1176\u002Fajp.148.8.997",{"doi":1123},"10.1176\u002Fajp.148.8.997",{"id":18,"text":1125,"url":18,"identifiers":1126},"Thase, 1991, Severity of depression and response to cognitive behavior therapy, Am J Psychiatry, 148, 784, 10.1176\u002Fajp.148.6.784",{"doi":1127},"10.1176\u002Fajp.148.6.784",{"id":18,"text":1129,"url":18,"identifiers":1130},"Barber, 1996, The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy: empirical findings from the treatment for depression collaborative research program, J Consult Clin Psychol, 64, 951, 10.1037\u002F0022-006X.64.5.951",{"doi":1131},"10.1037\u002F0022-006X.64.5.951",{"id":18,"text":1133,"url":18,"identifiers":1134},"Leykin, 2007, Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression, J Consult Clin Psychol, 75, 267, 10.1037\u002F0022-006X.75.2.267",{"doi":1135},"10.1037\u002F0022-006X.75.2.267",{"id":18,"text":1137,"url":18,"identifiers":1138},"Hollon, 2005, Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment?, J Clin Psychiatry, 66, 455, 10.4088\u002FJCP.v66n0408",{"doi":1139},"10.4088\u002FJCP.v66n0408",{"id":18,"text":1141,"url":18,"identifiers":1142},"Shea, 1990, Personality disorders and treatment outcome in the NIMH Treatment of Depression Collaborative Research Program, Am J Psychiatry, 147, 711, 10.1176\u002Fajp.147.6.711",{"doi":1143},"10.1176\u002Fajp.147.6.711",{"id":18,"text":1145,"url":18,"identifiers":1146},"Hardy, 1995, Impact of cluster C personality disorders on outcome of contrasting brief psychotherapies for depression, J Consult Clin Psychol, 63, 997, 10.1037\u002F0022-006X.63.6.997",{"doi":1147},"10.1037\u002F0022-006X.63.6.997",{"id":18,"text":1149,"url":18,"identifiers":1150},"McBride, 2006, Attachment moderator of treatment outcome in major depression: a randomized control trial of interpersonal psychotherapy versus cognitive behavior therapy, J Consult Clin Psychol, 74, 1041, 10.1037\u002F0022-006X.74.6.1041",{"doi":1151},"10.1037\u002F0022-006X.74.6.1041",{"id":18,"text":1153,"url":18,"identifiers":1154},"Joyce, 2007, Temperament, character and personality disorders as predictors of response to interpersonal psychotherapy and cognitive-behavioral therapy for depression, Br J Psychiatry, 190, 503, 10.1192\u002Fbjp.bp.106.024737",{"doi":1155},"10.1192\u002Fbjp.bp.106.024737",{"id":18,"text":1157,"url":18,"identifiers":1158},"Leykin, 2007, The relation of patients' treatment preference to outcome in a randomized clinical trial, Behav Ther, 38, 209, 10.1016\u002Fj.beth.2006.08.002",{"doi":1159},"10.1016\u002Fj.beth.2006.08.002",{"id":18,"text":1161,"url":18,"identifiers":1162},"Kocsis, 2009, Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or the combination, J Clin Psychiatry, 70, 354, 10.4088\u002FJCP.08m04371",{"doi":1163},"10.4088\u002FJCP.08m04371",{"id":18,"text":1165,"url":18,"identifiers":1166},"Keller, 1983, Dysfunctional attitudes and the cognitive therapy for depression, Cognit Ther Res, 7, 437, 10.1007\u002FBF01187171",{"doi":1167},"10.1007\u002FBF01187171",{"id":18,"text":1169,"url":18,"identifiers":1170},"Castonguay, 1996, Predicting the effect of cognitive therapy for depression: a study of unique and common factors, J Consult Clin Psychol, 64, 497, 10.1037\u002F0022-006X.64.3.497",{"doi":1171},"10.1037\u002F0022-006X.64.3.497",{"id":18,"text":1173,"url":18,"identifiers":1174},"Krupnick, 1996, The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program, J Consult Clin Psychol, 64, 532, 10.1037\u002F0022-006X.64.3.532",{"doi":1175},"10.1037\u002F0022-006X.64.3.532",{"id":18,"text":1177,"url":18,"identifiers":1178},"Burns, 1992, Therapeutic empathy and recovery from depression in cognitive-behavioral therapy: a structural equation model, J Consult Clin Psychol, 60, 441, 10.1037\u002F0022-006X.60.3.441",{"doi":1179},"10.1037\u002F0022-006X.60.3.441",{"id":18,"text":1181,"url":18,"identifiers":1182},"Burns, 1991, Coping styles, homework compliance, and the effectiveness of cognitive-behavioral therapy, J Consult Clin Psychol, 59, 305, 10.1037\u002F0022-006X.59.2.305",{"doi":1183},"10.1037\u002F0022-006X.59.2.305",{"id":18,"text":1185,"url":18,"identifiers":1186},"Shaw, 1999, Therapist competence ratings in relation to clinical outcome in cognitive therapy for depression, J Consult Clin Psychol, 67, 837, 10.1037\u002F0022-006X.67.6.837",{"doi":1187},"10.1037\u002F0022-006X.67.6.837",{"id":18,"text":1189,"url":18,"identifiers":1190},"DeRubeis, 1990, Determinants of change in cognitive therapy for depression, Cognit Ther Res, 14, 469, 10.1007\u002FBF01172968",{"doi":1191},"10.1007\u002FBF01172968",{"id":18,"text":1193,"url":18,"identifiers":1194},"Feeley, 1999, The temporal relation of adherence and alliance to symptom change in cognitive therapy for depression, J Consult Clin Psychol, 67, 578, 10.1037\u002F0022-006X.67.4.578",{"doi":1195},"10.1037\u002F0022-006X.67.4.578",{"id":18,"text":1197,"url":18,"identifiers":1198},"Imber, 1990, Mode-specific effects among three treatments for depression, J Consult Clin Psychol, 58, 352, 10.1037\u002F0022-006X.58.3.352",{"doi":1199},"10.1037\u002F0022-006X.58.3.352",{"id":18,"text":1201,"url":18,"identifiers":1202},"Simons, 1984, The process of change in cognitive therapy and pharmacotherapy for depression, Arch Gen Psychiatry, 41, 45, 10.1001\u002Farchpsyc.1984.01790120049007",{"doi":1203},"10.1001\u002Farchpsyc.1984.01790120049007",{"id":18,"text":1205,"url":18,"identifiers":1206},"Hollon, 1987, Causal mediation of change in treatment for depression: discriminating between nonspecificity and noncausality, Psychol Bull, 102, 139, 10.1037\u002F0033-2909.102.1.139",{"doi":1207},"10.1037\u002F0033-2909.102.1.139",{"id":18,"text":1209,"url":18,"identifiers":1210},"DeRubeis, 1990, How does cognitive therapy work? Cognitive change and symptom change in cognitive therapy and pharmacotherapy for depression, J Consult Clin Psychol, 58, 862, 10.1037\u002F0022-006X.58.6.862",{"doi":1211},"10.1037\u002F0022-006X.58.6.862",{"id":18,"text":1213,"url":18,"identifiers":1214},"Strunk, 2007, Patients' competence in and performance of cognitive therapy skills: relation to the reduction of relapse risk following treatment for depression, J Consult Clin Psychol, 75, 523, 10.1037\u002F0022-006X.75.4.523",{"doi":1215},"10.1037\u002F0022-006X.75.4.523",{"id":18,"text":1217,"url":18,"identifiers":1218},"Teasdale, 2001, How does cognitive therapy prevent relapse in residual depression? Evidence from a controlled trial, J Consult Clin Psychol, 69, 347, 10.1037\u002F0022-006X.69.3.347",{"doi":1219},"10.1037\u002F0022-006X.69.3.347",{"id":18,"text":1221,"url":18,"identifiers":1222},"Beevers, 2005, Unlinking negative cognition and symptoms of depression: evidence of a specific treatment effect for cognitive therapy, J Consult Clin Psychol, 73, 68, 10.1037\u002F0022-006X.73.1.68",{"doi":1223},"10.1037\u002F0022-006X.73.1.68",{"id":18,"text":1225,"url":18,"identifiers":1226},"Segal, 2006, Cognitive reactivity to sad mood provocation and the prediction of depressive relapse, Arch Gen Psychiatry, 63, 749, 10.1001\u002Farchpsyc.63.7.749",{"doi":1227},"10.1001\u002Farchpsyc.63.7.749",{"id":18,"text":1229,"url":18,"identifiers":1230},"Tang, 1999, Sudden gains and critical sessions in cognitive-behavioral therapy for depression, J Consult Clin Psychol, 67, 894, 10.1037\u002F0022-006X.67.6.894",{"doi":1231},"10.1037\u002F0022-006X.67.6.894",{"id":18,"text":1233,"url":18,"identifiers":1234},"Hardy, 2005, Sudden gains in cognitive therapy for depression: a replication and extension, J Consult Clin Psychol, 73, 59, 10.1037\u002F0022-006X.73.1.59",{"doi":1235},"10.1037\u002F0022-006X.73.1.59",{"id":18,"text":1237,"url":18,"identifiers":1238},"Tang, 2005, Cognitive changes, critical sessions, and sudden gains in cognitive-behavioral therapy for depression, J Consult Clin Psychol, 73, 168, 10.1037\u002F0022-006X.73.1.168",{"doi":1239},"10.1037\u002F0022-006X.73.1.168",{"id":18,"text":1241,"url":18,"identifiers":1242},"Tang, 2007, Sudden gains in cognitive therapy of depression and depression relapse\u002Frecurrence, J Consult Clin Psychol, 75, 404, 10.1037\u002F0022-006X.75.3.404",{"doi":1243},"10.1037\u002F0022-006X.75.3.404",{"id":18,"text":1245,"url":18,"identifiers":1246},"Vittengl, 2005, Validity of sudden gains in acute phase treatment of depression, J Consult Clin Psychol, 73, 173, 10.1037\u002F0022-006X.73.1.173",{"doi":1247},"10.1037\u002F0022-006X.73.1.173",{"id":18,"text":1249,"url":18,"identifiers":1250},"Jacobson, 1996, A component analysis of cognitive-behavioral treatment for depression, J Consult Clin Psychol, 64, 295, 10.1037\u002F0022-006X.64.2.295",{"doi":1251},"10.1037\u002F0022-006X.64.2.295",{"id":1253,"createTime":1254,"updateTime":1255,"relativeEntities":1256,"slug":1257,"properties":1258,"entityType":115,"verifyStatus":350,"verifyTime":1255,"verifyNote":351,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"primaryUrl":1265,"fullTextUrl":18,"authors":1266,"publicationType":134,"publisherRelationship":1282,"citationCount":18,"citationInfo":18,"publishDate":1315,"publishYear":1316,"citationAnalyzeStatus":17,"lastCitationAnalyze":18,"indexDatabases":18,"openAccess":18,"references":18,"isForceReanalyzing":170},"096312bd-4015-4c03-9fcf-ddb4c05aaec5","2024-01-17T09:18:02.758+00:00","2025-01-21T23:40:15.700+00:00",[],"The-Combined-Use-of-Psychotherapy-and-Pharmacotherapy-in-the-Medical-Setting",{"references":1259,"title":1261,"doi":1263},{"VOID":1260},"Caplan, 1964\nFreud, 1956\nGarrick, 1982, How to write a psychiatric consultation, Am J Psychiatry, 139, 849, 10.1176\u002Fajp.139.7.849\nGroves, 1975, Management of the broderline patient on a medical or surgical ward. The psychiatric consultant’s role, Int J Psychiatry Med, 6, 337, 10.2190\u002F5EQU-KW17-VGPL-9D67\nKahana, 1964, Personality types in medical management, 108\nKucharisk, 1977, The so-called “inappropriate” psychiatric consultation request on a medical or surgical ward, Int J Psychiatry Med, 7, 209, 10.2190\u002FGF4H-KB50-5YFW-GG8X\nMendelson, 1961, Countertransference problems of the liaison psychiatrist, Psychiatry, 23, 115\nMiller, 1973, Psychiatric consultation: Part II. Conceptual and pragmatic issues of formulation, Int J Psychiatry Med, 4, 251\nMuskin, 1983, The use of tricyclic antidepressants in a medical setting, 137\nMuskin, 1986, A new drug for the treatment of agitation in the general medical setting: Chlorpromazine, Gen Hosp Psychiatry, 8, 404, 10.1016\u002F0163-8343(86)90020-4\nPerry, 1981, Adaptations of residents to consultation-liaison psychiatry: I. Working with the physically ill, Gen Hosp Psychiatry, 3, 141, 10.1016\u002F0163-8343(81)90056-6\nPerry, 1981, Adaptation of residents to consultation-liaison psychiatry: II. Working with the nonpsychiatric staff, Gen Hosp Psychiatry, 3, 149, 10.1016\u002F0163-8343(81)90057-8\nPopkin, 1985, The outcome of antidepressant use in the medically ill, Arch Gen Psychiatry, 42, 1160, 10.1001\u002Farchpsyc.1985.01790350034007\nPopkin, 1980, Consultee’ concordance with consultants’ psychotropic drug recommendations, Arch Gen Psychiatry, 37, 1017, 10.1001\u002Farchpsyc.1980.01780220055005\n1956\nStoudemire, 1987, Psychopharmacology in the medically ill, 79\nViederman, 1983, The psychodynamic life narrative: A psychotherapeutic intervention useful in crisis situations, Psychiatry, 46, 236, 10.1080\u002F00332747.1983.11024196",{"EN":1262},"The Combined Use of Psychotherapy and Pharmacotherapy in the Medical Setting",{"VOID":1264},"10.1016\u002Fs0193-953x(18)30372-1","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0193953X18303721",[1267],{"id":1268,"sortIndex":19,"researcher":18,"roles":1269,"affiliations":1270,"properties":1279},"f45c9459-28c0-4025-88c7-f1740b27225f",[122],[1271],{"id":18,"sortIndex":19,"affiliation":1272,"properties":18},{"id":1273,"createTime":1274,"updateTime":1274,"relativeEntities":1275,"slug":18,"properties":1276,"entityType":39,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19},"a9bf6b47-84e6-498d-b9cc-58d9e3dae6aa","2024-01-17T09:18:02.770+00:00",[],{"title":1277},{"VI":1278},"Associate Clinical Professor of Psychiatry, College of Physicians and Surgeons, Collaborating Psychoanalyst, Psychoanalytic Center for Training and Research, Columbia University; Associate Chief of Service, Consultation\u002FLiaison Psychiatry, Columbia Presbyterian Hospital, New York, New York",{"title":1280},{"VI":1281},"Philip R. Muskin",{"url":1265,"publisher":1283,"properties":1310},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1284,"slug":10,"properties":1285,"entityType":16,"verifyStatus":17,"verifyTime":18,"verifyNote":18,"syncStatus":17,"languages":18,"translateLanguages":18,"viewCount":19,"subjectFields":1288,"manageAffiliations":1289,"indexDatabases":1290,"url":18,"thumbnailPath":18,"statistic":1305,"gsStatistic":18,"type":18,"analyzePriority":18},[],{"issn":1286,"title":1287},{"VOID":13},{"EN":15},[],[],[1291,1298],{"id":55,"indexDatabase":1292,"url":68,"indexYears":69,"academicFieldIds":1297,"indexDatabaseRanking":72},{"id":57,"createTime":58,"updateTime":59,"relativeEntities":1293,"label":1294,"description":1295,"key":65,"publicationTags":1296,"standard":18},[],{"EN":62,"VI":62},{"EN":62,"VI":64},[67],[71],{"id":74,"indexDatabase":1299,"url":89,"indexYears":18,"academicFieldIds":1304,"indexDatabaseRanking":18},{"id":76,"createTime":77,"updateTime":78,"relativeEntities":1300,"label":1301,"description":1302,"key":85,"publicationTags":1303,"standard":18},[],{"EN":81,"VI":81},{"VI":83,"EN":84},[87,88],[91],{"impactFactor":19,"impactFactorByYear":1306,"i10Index":19,"i10IndexLast5Year":19,"totalPublication":94,"totalPublicationByYear":1307,"totalCitation":19,"totalCitationByYear":1308,"totalCitationPerPublication":19,"totalCitationPerPublicationByYear":1309,"hindexLast5Year":19,"hindex":19},{},{"1992":94},{},{},{"volume":1311,"pages":1313},{"VOID":1312},"13",{"VOID":1314},"341-353","1990-06-01",1990]